UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                 --------------

                                  FORM 10-KSB/A


          [X] ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

                  For the annual period ended December 31, 2004

        [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

              For the transition period from _________ to _________



                               SECURED DATA, INC.

                                 --------------

                 (Name of Small Business Issuer in Its Charter)

<TABLE>
<CAPTION>
<S>                               <C>                   <C>
            NEVADA                Commission File No:                87-0650264
(State or other jurisdiction of        000-32253        (I.R.S. Employer Identification No.)
incorporation or organization)
</TABLE>

 16B/F Ruixin Road Bldg. No. 25 Gaoxin Road Xi An 710075 Shaanxi Province, China
                    (Address of principal executive offices)

                           (86) 29 8824 6358 (Issuer's
                     telephone number, including area code)

        Securities Registered Pursuant to Section 12(b) of the Act: None

           Securities Registered Pursuant to Section 12(g) of the Act:

                    Common Stock, Par Value $0.001 Per Share
                                (Title of Class)

            Check whether the issuer (1) filed all reports required to be filed
      by Section 13 or 15(d) of the exchange Act during the past 12 months (or
      for such shorter period that the registrant was required to file such
      reports); and (2) has been subject to such filing requirements for the
      past 90 days.

               Yes |X|        No |_|

            Check if there is no disclosure of delinquent filers in response to
      Item 405 of Regulation S-B contained in this form, and no disclosure will
      be contained, to the best of registrant's knowledge, in definite proxy or
      information statements incorporated by reference in Part III of this Form
      10-KSB or any amendment to this Form 10-KSB. |_|

            The issuer's revenues for the fiscal year ended December 31, 2004
      were $2,478,763.

            The aggregate market value of the common stock held by
      non-affiliates as of March 31, 2005 was $2,874,187.

            State the number of shares outstanding of each of the issuer's
      classes of equity securities, as of the latest practicable date:

      Title of Each Class of Equity       Number of Shares Outstanding as of
      Securities                          December 31, 2004
      -----------------------------       ----------------------------------
      Common Stock, $0.001 par value      39,604,958

      Transitional Small Business Disclosure Format (check one):  Yes |_| No |X|

<PAGE>

                                TABLE OF CONTENTS



PART I
                 ITEM 1.   Description of Business
                 ITEM 2.   Description of Properties
                 ITEM 3.   Legal Proceedings
                 ITEM 4.   Submission of Matters to a Vote of Security Holders
PART II
                 ITEM 5.   Market for Common Equity and Related Stockholder
                           Matters
                 ITEM 6.   Management's Discussion and Analysis
                 ITEM 7.   Financial Statements
                 ITEM 8.   Changes in and Disagreements with Accountants on
                           Accounting and Financial Disclosures
                 ITEM 8A.  Controls and Procedures
                 ITEM 8B.  Other Information
PART III
                 ITEM 9.   Directors, Executive Officers, Promoters and Control
                           Persons, Compliance With Section 16(A) of the
                           Exchange Act
                 ITEM 10.  Executive Compensation
                 ITEM 11.  Security Ownership of Certain Beneficial Owners and
                           Management
                 ITEM 12.  Certain Relationships and Related Transactions
                 ITEM 13.  Exhibits
                 ITEM 14.  Principal Accounting Fees and Services


                                       ii
<PAGE>

      This annual report contains certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. These include statements
about our expectations, beliefs, intentions or strategies for the future, which
we indicate by words or phrases such as "anticipate," "expect," "intend,"
"plan," "will," "we believe," "our company believes," "management believes" and
similar language. These forward-looking statements are based on our current
expectations and are subject to certain risks, uncertainties and assumptions,
including those set forth in the discussion under Item 1. Description of
Business" and Item 6. "Management's Discussion and Analysis", including under
the heading "- Risk Factors" under Item 6. Our actual results may differ
materially from results anticipated in these forward-looking statements. We base
our forward-looking statements on information currently available to us, and we
assume no obligation to update them. In addition, our historical financial
performance is not necessarily indicative of the results that may be expected in
the future and we believe that such comparisons cannot be relied upon as
indicators of future performance.

      Certain financial information included in this annual report has been
derived from data originally prepared in Renminbi (RMB), the currency of the
People's Republic of China. For purposes of this annual report, a conversion
rate of US$1.00 to RMB 8.3 was utilized. There is no assurance that RMB amounts
could have been or could be converted into US dollars at that rate.

      Secured Data, Inc., through its subsidiary Northwest BioTechnic Inc.
("NBTI") owns and operates, Huifeng Biochemistry Joint Stock Company
("Huifeng"), which is a joint venture company established under the laws of the
People's Republic of China ("PRC" or "China") with its main business as
production and sales of plant extracts, biochemical products and pharmaceutical
raw products in the PRC.


                                      iii
<PAGE>

                                     PART I

ITEM 1. DESCRIPTION OF BUSINESS

HISTORY

      Our company, Secured Data, Inc. ("we", "us", "our", "SCRE", the "Company"
or "our Company"), was incorporated under the laws of the State of Nevada and
trades on the Over the Counter ("OTC") Bulletin Board under the symbol "SCRE".

      Secured Data, Inc. is a corporation formed under the laws of the State of
Nevada on March 16, 2000. During the year 2000, we acquired a license to market
VitaMineralHerb.com products to customers in Oklahoma and New Mexico.
VitaMineralHerb.com hosts an Internet web site where health related products can
be purchased for resale; the web site then automatically credits the licensee
with purchases from their customers. We did not generate any revenues from the
above endeavors and during March 2002, we decided to terminate our involvement
with marketing vitamins and such related projects; consequently, we cancelled
our license agreement with VitaMineralHerb.com. Since October 2002, management's
business plan was to seek out a privately held business with whom the Company
can reorganize so as to take advantage of the Company's status as a publicly
held corporation.

      On December 20, 2004, pursuant to the terms of a Stock Purchase Agreement
("Malone Agreement"), Art Malone, Jr. ("Selling Shareholder") sold 7,229,601
shares of the common stock of Secured Data, Inc. ("Company") for $300,000 (the
"Sale") to Zhi Lan Wang and Jun Lin, individuals, on the closing date of
December 20, 2004. Such 7,229,601 shares of the common stock of the Company
represented approximately 56.18% of the total outstanding stock of the Company
as of that date.

      Immediately thereafter, pursuant to the terms of an Agreement and Plan of
Reorganization dated December 20, 2004 ("Northwest Agreement"), the Company
agreed to purchase all of the outstanding shares of Northwest BioTechnic, Inc.
("NBTI"), a British Virgin Islands corporation (the "Acquisition"). NBTI was
incorporated in the British Virgin Islands on June 25, 2004.

      At the time of the Acquisition, NBTI had a total of 500,000 shares issued
and outstanding, 250,000 of which were held by Jing An Wang, and 50,000 each
were held by Xinwen Hou, Zhang Jungi, Wang Bijun, Wang Zhilan, and Wang Xugang
(the "NBTI Shareholders"). Pursuant to the terms of the Northwest Agreement, at
the closing of the Acquisition, the Company delivered the following
consideration to the NBTI Shareholders: (i) 80,735,590 newly-issued shares of
the common stock of the Company (the "Initial NBTI Consideration") in exchange
for 30% of the total outstanding shares of NBTI (such shares of the common stock
of the Company allocated among the NBTI Shareholders on a pro rata basis
according to their respective ownership of NBTI); and (ii) a promissory note
(the "Promissory Note") payable to the NBTI Shareholders for the total amount of
$1,900,000, in exchange for the remaining 70% of the total outstanding shares of
NBTI. The Promissory Note is convertible into 10,465,725 shares of the Company's
common stock (allocated among the NBTI Shareholders on a pror rata basis
according to their respective ownership of NBTI), with such number of shares
calculated assuming the completion of a one-for-eighteen reverse split of the
Company's common stock prior to such conversion. Based on the current ownership
of NBTI shares by the NBTI Shareholders, Jing An Wang would receive 5,232,860
shares of the Company's common stock upon conversion, and each of Xinwen Hou,
Zhang Jungi, Wang Bijun, Wang Zhilan, and Wang Xugang would receive 1,046,573
shares of the Company's common stock. The Company currently expects that the
Promissory Note will be so converted.

      In summary, following the closing of the Acquisition, the total number of
outstanding shares of the Company's common stock was 93,604,958, which is also
the current total number of outstanding shares of the Company's common stock.


                                       1
<PAGE>

The Initial NBTI Consideration represents approximately 86.3% of that number of
shares. Giving effect to the intended one-for-eighteen reverse stock split, the
total number of outstanding shares of the Company's common stock will be
approximately 5,200, 277. Upon conversion of the Promissory Note (and assuming
completion of the one-for-eighteen reverse stock split), the total number of
outstanding shares of the Company's common stock will be approximately
15,666,002. Following such conversion, the total number of shares issued by the
Company as consideration for the Acquisition will represent approximately 95.4%
of the total outstanding common stock of the Company.

      The following chart illustrates the foregoing description of the
outstanding shares of the Company's common stock, and the ownership thereof by
the Company's principal officers, directors and affiliates.

<TABLE>
<CAPTION>
                                                                                               After Conversion of
                                Current Holdings              After Reverse Split                Promissory Note
                                ----------------              -------------------                ---------------
                           Shares Held              %     Shares Held                %     Shares Held                %
<S>                        <C>                  <C>       <C>                    <C>       <C>                    <C>
Jingan Wang                37,299,843           39.8%     2,072,214              39.8%     7,305,074              46.6%
Sanding Tao                3,633,102             3.9%     201,839                 3.9%     201,839                 1.3%
Xinwen Hou                 3,633,102             3.9%     201,839                 3.9%     1,248,412               8.0%
Xian Renfeng               9,284,593             9.9%     515,811                 9.9%     515,811                 3.3%
Investment Ltd.
Others                     39,754,318           42.5%     2,208,574              42.5%     6,394,866              40.8%
                           ---------------------------------------------------------------------------------------------

Total                      93,604,958          100.0%     5,200,277             100.0%     15,666,002            100.0%
</TABLE>


BUSINESS OVERVIEW

      The Company, through its wholly owned subsidiary NBTI, owns 100% of
Huifeng Biochemistry Joint Stock Company ("Huifeng"), which is a joint venture
company established under the laws of the PRC. Huifeng produces and sells plant
extracts, biochemical products and pharmaceutical raw products in the PRC.
Huifeng was founded on January 18, 2000. With its proprietary technology of
"Producing Rutin by Eliminating Enzyme and Mucus" together with abundant
resources of high quality pagoda rice in the Northwest region of China as raw
material, Huifeng developed and specialized itself as one of the major
technology-based Rutin companies in Xian provinces within two years after
establishment. Huifeng possesses one of the most advanced and patented
Rutin-refined technologies and is a major Rutin supplier in world market. There
are no regulatory requirements or other governmental restrictions in the PRC
that materially affect the Company's operations, other than normal regulations
covering the production of medicinal products discussed under "Government
Regulations" below.

      During 2004 and 2003, 100% of the Company's assets were located in China
and 90% of the Company's revenues were derived from companies located in China.

      The Company relied on two customers, Shandong Dai Yu Pharmaceutical
Company Limited and Shanxi Hon Lok Company Limited, for an aggregate of
approximately 63% of sales for the year ended December 31, 2004. The Company
relied on three customers, Shandong Dai Yu Pharmaceutical Company Limited,


                                       2
<PAGE>

Shanxi Hon Lok Company Limited and Wan Tat Pharmaceutical Company Limited, for
an aggregate of approximately 58% of sales for the year ended December 31, 2003.

         The Company relied on four suppliers, Fengsheng Ren, Zhixiang Gao,
Yangling Ai and Feng Li for an aggregate of 62% of purchases for the year ended
December 31, 2004. The Company relied on three suppliers, Feng Li, Cungui Zhang
and Shuyuan Li for an aggregate of 72% of purchases for the year ended December
31, 2003.

         The Company's patent application for its proprietary technology for
producing Rutin has been accepted and audited by the State Intellectual Property
Bureau of PRC (patent number: 02114402.8). This patent has been published on the
"Invention Patent Communique", volume 18, No 41. We own all the patent rights
and are the legal owners of such patent as shall be granted by the Chinese
government. See "Patents and Intellectual Property" below.

         The extractive process of producing Rutin - "Producing Rutin by
Eliminating Enzyme and Mucus" - is a patented technology with procedures as
follows: proprietary processes are used to purify raw material by using the
"Eliminating Enzyme" aspect of the process. The extracts are further processed
by another extraction procedure called "Eliminating Mucus" as extraction
material. The semi-finished product after the purification and extraction
process is further processed by "Alkali Extraction" and "Acid Deposition" to
obtain Rutin.

         The principal equipment required for Rutin extraction includes
enzyme-elimination tanks, pectin-elimination tanks, percolation tanks,
sedimentation tanks, plate and frame filter presses, drying machines,
disintegrators, and mixer blenders.

         The Rutin extraction process is assembly line work that runs
continuously. In general, the time for each main procedure is as follows:
fifteen minutes for enzyme-elimination; five minutes for eliminating pectin,
three hours for alkali extraction, six hours for acid precipitation, two hours
for filter pressing, and four hours for parching. The production process is
illustrated in the figure below:

<TABLE>
<CAPTION>
<S>                     <C>                   <C>                  <C>                   <C>
-----------------------                       --------------------                       --------------------------
                        Regular airing and                         Thermal steaming
pagoda rice raw         dust removal                               and                   Enzyme-elimination
material                                      Clean material       enzyme-elimination    material
-----------------------                       --------------------                       --------------------------
                                                                                         Eliminating pectin
-----------------------                       --------------------                       --------------------------
                        Disacidifying                              Alkali extraction
Rutin sediment          sediment              Extraction solution                        Eliminating pectin
                                                                                         material
-----------------------                       --------------------                       --------------------------

Filter pressing
-----------------------                       --------------------
                        Parching and
Filter mass             crashing              Rutin powder
-----------------------                       --------------------
</TABLE>

         Huifeng has emphasized technology and product innovation, and its
strategic mission is to commercialize Chinese traditional medicine. In this
regard, the Company's business missions are:

      (a)   To obtain Good Manufacturing Practice ("GMP") certification, which
            is awarded by the State Food and Drug Administration Bureau of the


                                       3
<PAGE>

            PRC government, for Huifeng's manufacturing facilities for medicine
            production;

      (b)   To build and operate the Company's raw material production site
            according to "GAP" standard, the certification standard for Chinese
            traditional medicine that was introduced and regulated by the State
            Food and Drug Administration Bureau of the PRC government that
            governs the production process to ensure quality in the production
            process;

      (c)   To build or modify the Company's facilities according to "GLP"
            standard, meaning "Medicine Quality System Regulation for
            Non-Clinic," that was introduced and regulated by the State Food and
            Drug Administration Bureau of the PRC government and considered an
            international standard for laboratories for advanced function of
            biological molecules development and production; and

      (d)   To develop natural cosmetics, health food and beverages using Rutin
            as raw materials.

      With respect to item (a) above, the GMP certification is awarded by the
provincial Food and Drug Supervisory Administration Bureau, whose jurisdiction
includes the treatment of procedures for raw materials, whole processes of
production, and quality control inspection. The process by which the GMP
certification is awarded is as follows:

      1.    The applicant applies to the provincial Food and Drug Supervisory
            Administration Bureau for project evaluation;

      2.    The applicant prepares for reconstruction according to GMP
            standards, which are stated in the following publications:

            a.    "Good Manufacturing Practice and Quality Control of Drug"
                  China, 1998 edition;
            b.    "US Pharmacopoeia" volume 23 drug quality standard 11th
                  edition (abbreviated as NF11);
            c.    "Germany Drug Quality" 9th and 10th edition (abbreviated as
                  DAB9 and DAB10);

      3.    The applicant applies to the provincial Food and Drug Supervisory
            Administration Bureau for an on-site check, following which the
            provincial Food and Drug Supervisory Administration Bureau arranges
            an on-site check after receiving GMP inspection data from the
            applicant (normally there are three inspectors to inspect the
            management, quality, facilities and documents of production /
            records, respectively);

      4.    The results will be announced publicly within 15 days thereafter and
            will also be sent to the National Food and Drug Supervisory
            Administration Bureau, which will inform the provincial Food and
            Drug Supervisory Administration Bureau to award the GMP certificate
            to the applicant if there is no objection from the public.

      The Company has made the following adjustments to meet the requirements of
GMP standards:

      1.    The Company's entire workshop has been redesigned and reconstructed
            according to GMP standards. There are production areas (including
            raw material plants, finished drug plants, spasmolytic plants),
            storage districts, quality test districts, administration districts
            and living quarters, which are divided and separated from each other
            in separate concrete rooms.

      2.    A set of equipment and instruments have been updated which comprise
            30B disintegrators, type 500 vacuum driers, SS800 three legged


                                       4
<PAGE>

            centrifugers, high performance liquid chromatographs, gas
            chromatographs and ultraviolet spectrophotometers.

      3.    We have organized every division to amend all administrative
            documents to meet the requirements of GMP standards, which satisfies
            the process, operation and standardization requirements of GMP
            standards.

      4.    We have implemented GMP training for all staff from senior managers
            to line workers, to educate them on the essentials of the GMP
            standards in order to ensure the quality of our products.

      5.    We have organized the skill training programs and examinations for
            our workers according to their role and positions to ensure that
            they are qualified to work.

      With respect to item (b) above, the GAP standard applies to the daily
operations of the Company during the manufacturing process. According to the GAP
standard, testing standards have been drawn up by the Company's management in
order to make the contents and impurity of pagoda rice come within a
controllable capacity. Such standards have been prepared on the basis of the
geographical environment for growth of pagoda rice.

      Our company strictly operates in accordance with the GAP standard; for
instance, we select the pagoda rice according to our standards and procedures
developed under the GAP standard while purchasing the raw material to guarantee
the raw material is of stable quality.

      With respect to item (c) above, the existing physical conditions of the
Company's research laboratory need substantial modifications, including, but not
limited to, an increase in the floor area of the laboratory, renovation of the
internal set up of the laboratory, the purchase of new laboratory equipment, and
improvement to the environment to conduct research. It is estimated that a
minimum of $120,000 will be required for this modification and the Company
intends to implement it after raising funds for the Company.

OUR PRODUCTS

         Huifeng produces a series of Rutin and Rutin-related products:

         Pharmaceutical Intermediates   1. NF11 Rutin (USP standard)
                                        2. DAB8iBDAB9iBDAB10iBDAB11
                                           Rutin (German Codex Standard)
                                        3. Troxerutin (farinaceous
                                           injectioniBoral application)
                                        4. Quercetin, L-Rhamnone

         Pharmaceutical Material        1. Venoruton (farinaceous
                                           injectioniBoral application)
                                        2. Rutin
                                        3. Berberine Hydrochlorrde
                                        4. Matrine

         Plant Extractive               1. Hesperidin
                                        2. Naringin
                                        3. Epimedium Extract
                                        4. Matrine
                                        5. Pueraria
                                        6. Siybun Marianum P.E

         The chemical name of Rutin is rue glycoside (Molecular formula:


                                       5
<PAGE>

C27H30O163H2O) and it is a kind of plant extract. According to numerous academic
and medical research reports, Rutin has the following effects and uses:

      1.    It can inhibit platelet aggregation and prevent thrombosis;

      2.    It can also improve the permeability of capillary vessel, and has
            the properties of:

            a.    Anti-inflammatory;

            b.    Decreasing blood pressure and fat; and

            c.    Mitigating cerebral hemorrhage.

      3.    It has a positive effect in protecting heart and cerebral hemorrhage
            and ischemia-reperfusion injury.

      4.    It is widely used as raw material for heart and cerebra blood vessel
            medicines as well as additive for cosmetic and functional food.

      The improvement in living standards in China has stimulated the growth in
demand of functional food and natural cosmetics like Rutin.

PRODUCTION FACILITIES

      In 2004 Huifeng has two major production facilities, and the equipment
resources of each of the facilities are as follows:

      1.    Manufacturing plant located at NO 1,Huifeng Rd, Changwu, Xianyang:

            o     This production site is for refining and manufacturing of new
                  products

            o     Has a total of ten buildings including:

            o     A two levels office building

            o     A four levels staff building

            o     Three manufacturing buildings (including extract workshops,
                  refining workshops and packaging workshops)

            o     One raw materials storage building

            o     One building for storage of finished products

            o     One building for dangerous products

            o     Building for power and maintenance (including boiler, power
                  distribution and maintenance)

            o     One cafeteria and staff canteen

            o     The production capacity of the plant is approximately 500
                  tons/year

      2.    Manufacturing plant located in Fenghui, Changan, Xian

      o     This production site is for extract and supplies raw materials for
            refining

      o     Has a total of four buildings including:

      o     One office building

      o     One manufacturing building (including extract workshops,
            crystallization workshops, communication workshops and packaging
            workshops),


                                       6
<PAGE>

      o     One raw materials building

      o     One boiler

      o     The production capacity of the plant is approximately 300 tons/year

         The two production facilities together occupy a total area of
approximately 300,000 square feet. The existing utilization rates of the two
plants are approximately 60% to70%. The general physical condition of the plants
and production facilities of the Company can completely satisfy the production
needs of the Company in terms of quantity and production quality for the near
future.

         Raw materials and ingredients, such as carbinol and hydrochloric acid,
which are needed in the manufacturing or refining process during production of
our products, are dangerous chemicals that require special handling. Our
building for dangerous products is constructed according to the GMP standards.
These raw materials are stored separately in our building for dangerous products
to avoid or minimize dangers related to storage and applications of these
special raw materials and ingredients.

      We use two kinds of dangerous material during the production process:
methanol, which is a combustible material, is used as a side material during the
production process; and hydrochloric acid, which is corrosive in nature, is also
used as another side material. These materials are stored; deposited and
utilized according to the standard requirements for dangerous articles.
Specifically, these dangerous materials are delivered to the production
facilities using dedicated pipelines and airproof ducts. During the production
process, there is a central air-conditioning system that maintains stable room
temperature from 18oC to 26oC. Smoking or lighting fires is strictly forbidden
inside the production facilities, and the production process is conducted in
accordance with our standard operation manual for dangerous articles.

TARGET MARKETS AND PRINCIPAL CUSTOMERS

         All of Huifeng's products are raw materials for production of medicines
and the users of these products are industrial clients. As a result, Huifeng's
main target customers are pharmaceutical companies and food manufacturers.

         For the year ended December 31, 2004, $2,177,478 or 87.8% of our sale
revenues was derived from sales of Rutin and Rutin-related pharmaceutical
intermediates and material. $301,285 or 12.2% of our sales revenues was derived
from sales of plant extracts.

SALES AND MARKETING

         Since the majority of Huifeng's products are raw materials for
production of medicines and target customers are mostly industrial clients,
Huifeng sells and distributes its products mainly through direct selling to
medicine and food manufacturers. Usually customers will place purchase orders
directly with the sales and marketing team of Huifeng.

         Refined products and the refining process refers to the refining of raw
material into Rutin, and Rutin itself is a raw material provided to other
pharmaceutical companies and food manufacturers, who are all customers of our
Company.

         The organizational structure of the sales and marketing team of Huifeng
is as follows: our sales director manages the whole sales team through sales
managers, and each of the sales managers controls a team of sales supervisors
and salesmen.


                                       7
<PAGE>

         Huifeng also participates in distribution and marketing activities that
aim at strengthening its ties with existing and new customers. One
frequently-used technique to expand our distribution network and develop new
customers is participation in various domestic and international medicine raw
materials exhibitions. Also, Huifeng focuses on improving the quality of
products and after-sale services in order to better maintain customer
relationships.

COMPETITION

         Huifeng engages in Rutin production in China. With its proprietary
technology of "Producing Rutin by Eliminating Enzyme and Mucus" and with
abundant resources of high quality pagoda rice in the Northwest region of China
as raw material, Huifeng has not faced substantial competition within China.
From time to time there are many small domestic Rutin manufacturers but the
Company believes that these companies will not pose a threat to Huifeng's
business expansion in China.

         Based on similarity of products, pricing, and production scale, we
believe that the major competitor of Huifeng is Sichuan Xietong Pharmaceutical
Company Limited ("Xietong"). However, because of what we believe based on our
search of publicly available documents to be a lack of technological patents and
access to raw materials, we believe that Xietong is gradually fading out of the
Rutin refining business and is shifting its business from raw medicine
production to finished medicine production, and retains a rather small portion
of its business in raw medicine production. This information is based on market
information obtained from our customers and by our sales and marketing team.

      Although our competitors or potential competitors have an equivalent
opportunity to access raw materials as we do, the majority of our current
competitors, especially our potentially strong competitors, are not located in
the same geographical region as us, which is where the principal materials come
from. For instance, our main ingredient, pagoda rice, exists only in northern
parts of China. The transportation cost for raw material from our geographic
region would substantially increase our competitor's cost of production. As a
result, we believe that we will have competitive advantage over our competitors
in cost of production and hence we can sell our products at a lower price.

      Upon expiration of our patent, other competitors may utilize our
technologies to their advantage. However, we believe that we can improve our own
products during the time period prior to expiration. See "Patents and
Intellectual Properties".


PRINCIPAL OFFICE

         Our principal office is located at FL16B, Ruixin Bldg, NO.25, Gaoxin
Rd, Xian China.

EMPLOYEES AND ORGANIZATION

         As of December 31, 2004, the Company's subsidiary, Huifeng, had
approximately 186 full-time employees, out of which approximately 75 are
technicians. None of our employees are covered by a collective bargaining
agreement, we have never experienced a work stoppage, and we consider our labor
relations to be excellent.

         The organization of Huifeng is divided into 8 departments that are
supervised by our chief executive officer: personnel department, financial
department, securities department, sales department, provision department,
inspection department, production department and R&D department. The production
department supervises the two manufacturing plants and the raw material
production site.


                                       8
<PAGE>

BUSINESS DEVELOPMENT AND ACQUISITIONS

         In 2005 we will focus on:

         1.   Increasing Huifeng's market share for Rutin in both the
              international and domestic market

         2.   Commercializing an additional one to two new products and striving
              to launch these products into the public market; and

         3.   Enlarging the organization and improving production efficiency.

PATENTS AND INTELLECTUAL PROPERTIES

         The patent system of China includes invention patents, practical
patents and shape patents. Patents granted under the Chinese patent system
protect the intellectual properties owned by the patent owner against
infringement by third parties. The only patents applied for or obtained by the
Company have been applied for by our subsidiary Huifeng, and are protected only
in the PRC. We have not applied for or obtained any international patents.

         Applying for a patent through the State Intellectual Property Bureau of
the PRC requires a substantial period of time. Huifeng's patent application for
"Producing Rutin by Eliminating Enzyme and Mucus" has been reported in volume
18, number 41 in the "Invention Patent Communique," which is the patent bulletin
board in China, and has been assigned the number of 02114402.8. The underlying
technology is a proprietary method to purify raw material, and process the
extracts to produce an extraction material that is subjected to further
processes called "Alkali Extraction" and "Acid Deposition" to obtain Rutin.
Assuming there is no objection, the formal patent certificate will be issued
after the bulletin period has expired. We estimate that the formal patent
certificate will be issued in December 2005.

         There are time limits for patent protection in China, which cannot be
extended following expiration of the patent protection period. Therefore,
relevant laws will not protect our patent after it expires, which is 15 years
after it is granted. It is possible that other companies or persons, especially
our competitors, may take advantage of such technology upon our patent expiry.
But, within the patent protection period, we believe we can develop ourselves to
produce much higher quality products using such patent technology and develop a
stable customer base for a larger market share. We also believe we can develop a
good reputation in our business sector within the patent protection period. As a
result, even though our competitors can access to such technology after the
patent protection period, we do not believe it will negatively affect our
overall competitive environment.


GOVERNMENT REGULATIONS

         To its knowledge, the Company has complied with all applicable
government regulations relating to its existence and conduct of business,
including business licensing and registration requirements under Nevada law. To
the Company's knowledge, its subsidiary, NBTI, has also complied with all
relevant government regulations.

         As pertaining to the Company's subsidiary in China, Huifeng, there are
several applicable governmental regulations. As an initial matter, a company
must apply for a business license if it wants to operate a business in China. If
the business scope requires approval according to government regulations, then
the company must apply for such approval as well. Without prior approval of the
administrative department in charge, no person or company can acquire a business
license.


         Specifically, to engage in the pharmaceutical business in China, a
company must apply for project approval from the provincial Food and Drug
Supervisory Administration Bureau and for a business license from the Industrial
and Commercial Bureau of Public Administration. Furthermore, such company would


                                       9
<PAGE>

need to apply for license for producing medicine, which would be granted with
filing numbers by the national and provincial Food and Drug Supervisory
Administration Bureaus. In this regard, according to provision file No. 288
(2003) of the Food and Drug Supervisory Administration Bureau, since July 1,
2004, the production of all medicines, pharmaceutics and raw material has to
meet the requirements of GMP standards. There is no compulsory requirement for
GMP certification prior to July 1 2004. After obtaining the foregoing, a company
would be allowed to produce medicine in China.

         Huifeng has obtained all relevant business and operational licenses, as
follows:

      1.    Huifeng obtained the required business license at the time of its
            organization.

      2.    Huifeng acquired the relevant certificate for producing medicine,
            which was approved by the provincial Food and Drug Supervisory
            Administration Bureau on December 30, 2000 (license number:
            ShanZz20000136).

      3.    On January 10, 2000, Huifeng was approved by the Chinese National
            Supervisory Administration Bureau of Foods and Drugs to produce
            "Rutin" and "Troxerutin" with approval numbers H61020677 and
            H61020678, respectively. On October 20, 2004, the Chinese National
            Supervisory Administration Bureau of Foods and Drugs issued a new
            license number H20045246 to replace license number H61020677 and a
            new license number H20045265 to replace license number H61020678.

      4.    On February 18, 2005, the provincial Food and Drug Supervisory
            Administration Bureau announced that Huifeng has met the
            requirements for GMP certification for medicine production.
            Therefore, a GMP certificate with certification number ShanG0110 was
            granted to the Company.

         In addition, there are two ordinances governing the manufacturing of
medical products in China: (1) the Ordinance for the Management of Medicine,
with a total of 111 articles governing safety issues in research, manufacture,
sales and use of medicine and medicinal products; and (2) the Ordinance for
Medical Product Manufacturing that governs the requirements in GMP
certifications to regulate the production environment, production facilities,
production equipment, production technologies and environment conservation
issues related to the production of medicine and medicinal products. To the
Company's knowledge, Huifeng is in compliance with both of these ordinances.

ITEM 2.       DESCRIPTION OF PROPERTIES

         See "production facilities" in ITEM 1 - DESCRIPTION OF BUSINESS.

         There is no lien or encumbrance on any of the mentioned properties.

ITEM 3        LEGAL PROCEEDINGS

         We are currently not involved in any litigation that we believe could
have a material adverse effect on our financial condition or results of
operations. There is no action, suit, proceeding, inquiry or investigation
before or by any court, public board, government agency, self-regulatory
organization or body pending or, to the knowledge of the executive officers of
our company or any of our subsidiaries, threatened against or affecting our
company, our common stock, any of our subsidiaries or of our company's or our
company's subsidiaries' officers or directors in their capacities as such, in
which an adverse decision could have a material adverse effect.


                                       10
<PAGE>

ITEM 4        SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         On March 23, 2005, the Board of Directors unanimously approved and
ratified a 1:18 reverse split (the "Reverse Split") of the Company's issued and
outstanding common stock and an amendment (the "Amendment") to its Articles of
Incorporation changing the name of the Company to "Huifeng Bio-pharmaceutical
Technology Inc.", subject to the approval of the Company's stockholders. The
record date established by the Board for purposes of determining the number of
outstanding shares of voting stock entitled to vote on the Reverse Split and the
Amendment was March 23, 2005 (the "Record Date"). On the Record Date,
stockholders owning 53,850,640 shares of Common Stock, or approximately 57.5% of
the issued and outstanding shares of Common Stock, approved the Reverse Split
and the Amendment by action taken without a meeting in accordance with Nevada
law. No further vote of our stockholders was required.

         As a result, the Company filed a preliminary information statement
pursuant to Section 14(c) of the Securities Exchange Act of 1934 on March 23,
2005 in connection with the approval by a majority of the stockholders of (i) an
amendment to its Articles of Incorporation effecting the Reverse Split and (ii)
the Amendment

         On the effective date of the Reverse Split the number of issued and
outstanding shares of common stock of the Company will be reduced from a total
of 93,604,958 shares which were outstanding on the Record Date, to approximately
5,200,275 shares.

         When filed with the Nevada Secretary of State, the Amendment will
change the name of the Company to "Huifeng Bio-pharmaceutical Technology Inc."

         However as of the date of this filing, this preliminary information
statement was still not approved by the Securities and Exchange Commission.



                                     PART II

ITEM 5        MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

         Our common stock is quoted on the Over-the-Counter Bulletin Board
("OTCBB") under the symbol "SCRE".

            Trading in our common stock has been limited and sporadic. The
following table shows the range of high and low bid quotations reported by the
OTCBB in each fiscal quarter from January 1, 2003 to December 31, 2004, and the
subsequent interim period. The OTCBB quotations reflect inter-dealer prices,
without retail mark-up, mark-down or commission, and may not represent actual
transactions. As of July 25, 2005, there were approximately 80 holders of record
of our common stock. This number does not include an indeterminate number of
shareholders whose shares are held by brokers in street name.

BID PRICES FOR THE REPORTING PERIOD

    Year                             Period               High        Low

    2003       First Quarter                                $0.040     $0.005
               Second Quarter                               $0.040     $0.010
               Third Quarter                                $0.015     $0.010
               Fourth quarter                               $0.020     $0.000

    2004       First Quarter                                $0.300     $0.010
               Second Quarter                               $0.070     $0.060
               Third Quarter                                $0.300     $0.050
               Fourth quarter                               $0.590     $0.020


                                       11
<PAGE>

    2005       First Quarter                                $0.160     $0.050
               Second Quarter                               $0.100     $0.040
               Third Quarter (through July 22, 2005)        $0.050     $0.035




DIVIDENDS

        We presently intend to retain future earnings, if any, to provide funds
for use in the operation and expansion of our business. Accordingly, we have not
declared or paid any dividends to our common shareholders and do not presently
intend to do so. Any future decision whether to pay dividends will depend on our
financial condition and any other factors that our Board of Directors deems
relevant.


ISSUANCE OF SHARES

         During the three month period ended June 30, 2004 the Company issued
6,232,290 shares of its common stock to Art Malone Jr. as repayment for his cash
advances to the Company that was used to operate the business of the Company.

         Between December 15, 2004 and December 20, 2004, the Company issued a
total of 585,000 shares of common stock to three creditors in exchange for
satisfaction and settlement of Company debts totaling $93,000.

         On December 20, 2004, the Company issued 80,735,590 shares of common
stock to the shareholders of NBTI in pursuant to the Acquisition as described in
the Section "History" of "ITEM 1 - DESCRIPTION OF BUSINESS"

      Unless otherwise noted, the sales set forth above involved no
underwriter's discounts or commissions and are claimed to be exempt from
registration with the Securities and Exchange Commission pursuant to Section 4
(2) of the Securities Act of 1933, as amended, as transactions by an issuer not
involving a public offering, the issuance and sale by the Company of shares of
its common stock to financially sophisticated individuals who are fully aware of
the Company's activities, as well as its business and financial condition, and
who acquired said securities for investment purposes and understood the
ramifications of same.


ITEM 6        MANAGEMENT'S DISCUSSION AND ANALYSIS

         This annual report contains forward-looking statements within the
meaning of the federal securities laws. These include statements about our
expectations, beliefs, intentions or strategies for the future, which we
indicate by words or phrases such as "anticipate," "expect," "intend," "plan,"
"will," "we believe," "SCRE believes," "management believes" and similar
language. The forward-looking statements are based on the current expectations
of SCRE and are subject to certain risks, uncertainties and assumptions,
including those set forth in the discussion under "Description of Business" and
"Management's Discussion and Analysis or Plan of Operation,". The actual results
may differ materially from results anticipated in these forward-looking
statements. We base the forward-looking statements on information currently
available to us, and we assume no obligation to update them.

         On December 20, 2004, pursuant to the Malone Agreement, Art Malone, Jr.
("Selling Shareholder") sold 7,229,601 shares of the common stock of the Company
for $300,000 (the "Sale") to Zhi Lan Wang and Jun Lin, individuals on the


                                       12
<PAGE>

closing date of December 20, 2004. Such 7,229,601 shares of the common stock of
the Company represented approximately 56.18% of the total outstanding stock of
the Company as of that date.

         Immediately thereafter, pursuant to the terms of an Agreement and Plan
of Reorganization dated December 20, 2004 ("Northwest Agreement"), the Company
agreed to purchase all of the outstanding shares of Northwest BioTechnic, Inc.
("NBTI"), a British Virgin Islands corporation (the "Acquisition"). NBTI was
incorporated in the British Virgin Islands on June 25, 2004.

         At the time of the Acquisition, NBTI had a total of 500,000 shares
issued and outstanding, 250,000 of which were held by Jing An Wang, and 50,000
each were held by Xinwen Hou, Zhang Jungi, Wang Bijun, Wang Zhilan, and Wang
Xugang (the "NBTI Shareholders"). Pursuant to the terms of the Northwest
Agreement, at the closing of the Acquisition, the Company delivered the
following consideration to the NBTI Shareholders: (i) 80,735,590 newly-issued
shares of the common stock of the Company (the "Initial NBTI Consideration") in
exchange for 30% of the total outstanding shares of NBTI (such shares of the
common stock of the Company allocated among the NBTI Shareholders on a pro rata
basis according to their respective ownership of NBTI); and (ii) a promissory
note (the "Promissory Note") payable to the NBTI Shareholders for the total
amount of $1,900,000, in exchange for the remaining 70% of the total outstanding
shares of NBTI. The Promissory Note is convertible into 10,465,725 shares of the
Company's common stock (allocated among the NBTI Shareholders on a pror rata
basis according to their respective ownership of NBTI), with such number of
shares calculated assuming the completion of a one-for-eighteen reverse split of
the Company's common stock prior to such conversion. Based on the current
ownership of NBTI shares by the NBTI Shareholders, Jing An Wang would receive
5,232,860 shares of the Company's common stock upon conversion, and each of
Xinwen Hou, Zhang Jungi, Wang Bijun, Wang Zhilan, and Wang Xugang would receive
1,046,573 shares of the Company's common stock.

         NBTI operates through its wholly owned subsidiary, Huifeng Biochemistry
Joint Stock Company ("Huifeng"), which is a joint venture company established
under the laws of China and is engaged in the production and sales of plant
extracts, biochemical products and pharmaceutical raw products in the PRC.

         The exchange was treated as a reverse acquisition for accounting
purposes. As such, the financial information reflected activity subsequent to
the acquisition of the Company and its subsidiaries and financial activity of
NBTI prior to the acquisition. We will continue the business operations
conducted by NBTI.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

         We have identified one policy area as critical to the understanding of
our consolidated financial statements. The preparation of our consolidated
financial statements requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the consolidated financial
statements and the reported amounts of sales and expenses during the reporting
periods. With respect to net realizable value of the Company's accounts
receivable and inventories, significant estimation judgments are made and actual
results could differ materially from these estimates.

         The Company does not have any reserves against its accounts receivable
or inventories at December 31, 2004 and 2003. Management's estimation that there
are no reserves is based on the current facts that there is no significant aged
accounts receivable and the current inventory turnover is sufficient to realize
the current carrying value of the inventories. In making their judgment,
management has assumed that there will be continued demand for their products in


                                       13
<PAGE>

the future, thereby maintaining adequate turnover of the inventories.
Additionally, management has assumed that customers will continue to pay their
outstanding invoices timely, and that their customers' financial position will
not deteriorate significantly in the future, which would result in their
inability to pay their debts to the Company. While the Company's management
currently believes that there is little likelihood that the actual results of
their current estimates will differ materially from its current estimates, if
customer demand for its products decreases significantly in the near future, or
if the financial position of its customers deteriorates in the near future, the
Company could realize significant write downs for slow moving inventories or
uncollectible accounts receivable.

         We believe the following is among the most critical accounting policies
that impact our consolidated financial statements. We suggest that our
significant accounting policies, as described in our consolidated financial
statements in the Summary of Significant Accounting Policies, be read in
conjunction with this Management's discussion and Analysis of Financial
Condition and Results of Operations.

         We recognize revenue in accordance with Staff Accounting Bulletin
("SAB") No. 104. All of the following criteria must exist in order for us to
recognize revenue:

         1. Persuasive evidence of an arrangement exists;

         2. Delivery has occurred or services have been rendered;

         3. The seller's price to the buyer is fixed or determinable and

         4. Collectibility is reasonably assured.

         The majority of the Company's revenue results from sales contracts with
distributors and revenue is generated upon the shipment of goods. The Company's
pricing structure is fixed and there are no rebate or discount programs.
Management conducts credit background checks for new customers as a means to
reduce the subjectivity of assuring collectibility. Based on these factors, the
Company believes that it can apply the provisions of SAB 104 with minimal
subjectivity.

RESULTS OF OPERATIONS

         The following table sets forth selected statement of operations data as
a percentage of revenues for the periods indicated.

                                             Year Ended          Year Ended
                                      December 31, 2004   December 31, 2003
                                      -----------------   -----------------

Revenues                                        100.00%                100%
Cost of Revenues                               (90.17%)            (95.47%)
Gross Margin                                      9.83%               4.53%
General and administrative expenses            (16.76%)             (5.83%)
Selling and distribution expenses               (1.68%)             (6.96%)
Depreciation and amortization                   (0.36%)             (0.77%)
Equity in loss of affiliate                     (0.00%)                  --
Interest income, net                              0.05%               7.23%
Other income, net                                 0.03%               0.04%
Income tax expenses                             (0.30%)                  --
Minority interest                                 0.34%               0.92%
Net Loss                                        (8.86%)             (0.84%)

YEAR ENDED DECEMBER 31, 2004 COMPARED TO YEAR ENDED DECEMBER 31, 2003


                                       14
<PAGE>

Revenues, Cost of Revenues and Gross Margin

Revenues, Cost of Revenues and Gross Margin

Revenues for the year ended December 31, 2004 were $2,478,763 an increase of
$1,762,904 from $715,859 for the year ended December 31, 2003. Our increases in
sales revenues in 2004 were mainly attributable to the increase in our sales of
the following products in 2004 against 2003:

<TABLE>
<CAPTION>
         Product                                          For the year ended December 31,                      Increase /
                                                                                                               (Decrease)
                                      ---------------------------------------------------
                                                      2004                           2003
---------------------------           ---------------------            -------------------           ---------------------
<S>                                   <C>                              <C>                           <C>
Pharmaceutical                        $          2,404,924             $          635,832            $           1,769,092
intermediates
Pharmaceutical material                              8,484                         12,964                          (4,480)
Plant Extractive and                                65,355                         67,063                          (1,708)
others

                                      ---------------------            -------------------           ----------------------
         TOTAL                        $          2,478,763             $          715,859            $           1,762,904
                                      =====================            ===================           ======================
</TABLE>


Cost of revenues for the year ended December 31, 2004 were $2,235,189, an
increase of $1,551,759 from $683,430 for the year ended December 31, 2003.
Compared to the year ended December 31, 2003, the increase in cost of sales of
our products was because of our increase in sales revenue in 2004 of the
following products against 2003:

<TABLE>
<CAPTION>
         Product                                          For the year ended December 31,                         Increase /
                                                                                                                  (Decrease)
                                      ----------------------------------------------------
                                                      2004                           2003
---------------------------           ---------------------            -------------------              ---------------------
<S>                                   <C>                              <C>                              <C>
Pharmaceutical                        $          2,163,890             $          604,040               $          1,559,850
intermediates
Pharmaceutical material                              7,636                         12,316                            (4,680)
Plant Extractive and                                63,663                         67,074                            (3,411)
others

                                      ---------------------            -------------------              ---------------------
         TOTAL                        $          2,235,189             $          683,430               $          1,551,759
                                      =====================            ===================              =====================
</TABLE>


                                       15
<PAGE>

However, the increase in cost of sales of our products was not in the same
proportion as our increase in sales revenue because our profit margin improved
in 2004 as compared to 2003. Our gross profit margin for 2004 improved from
4.53% in 2003 to 9.83% in 2004 as a result of our improved efficiency in
production due to economy of scale of production as sales volume increased.

         Gross margin for the year ended December 31, 2004 was $243,574, an
increase of $211,145 from $32,429 for the year ended December 31, 2003.

General and Administrative Expenses

         General and Administrative expenses totaled $ 415,342 for the year
ended December 31, 2004, an increase of $ 373,613 from $41,729 for the year
ended December 31, 2003. The increase in general and administrative expenses was
mainly due to an increase of $353,613 in general and administrative expenses in
Huifeng. The increase in general and administrative expenses in Huifeng was due
to an increase of $5,455 in salary expenses and $151,187 in office overhead as a
result of increased business activities. There were also one-time expenses of
$118,836 for factory relocation expenses and $78,135 for a special audit of
Huifeng. There were also $20,000 in expenses related to the Malone Agreement,
the Northwest Agreement and the Acquisition, which were all one-time events in
2004.

Selling and Distribution Expenses

         Selling and distribution expenses totaled $41,569 for the year ended
December 31, 2004, a decrease of $8,264 from $49,833 for the year ended December
31, 2003. Compared to the same year ended December 31, 2003, we increased $3,841
and $16,662 in salary expenses and overhead, respectively, for sales and
marketing staffs as a result of increase in number of employee. However, we
reduced our expenses on promotion material of $28,767 because in the same year
ended 2003, we incurred one-off expenses of purchase of promotion material that
was not repeated in 2004. The Company had not increased its expenses in sales
and distribution despite sales revenue increased, as most of the Company sales
in 2004 were direct selling to industrial customers that did not rely on
intensive sales and distribution activities.

Liquidity and Capital Resources

Cash

         Our cash balance amounted to $167,511 at December 31, 2004.

         In the year ended December 31, 2004, our cash used in operating
activities amounted to $526,363, mainly to due the net loss in the current year
amounted to $ 219,730. Also, in the current year, inventories and other
receivables increased by $405,019 and $236,920, respectively as a result of
increased in business activities. We experienced increase in inventory level in
2004 as a result of increased in production scale to capture economy of scale in
production to improve profit margin as well as stock up on raw material to
reduce raw material cost and as a result, or percentage profit margin improved
from 4.53% in 2003 to 9.83% in 2004. We also experienced increase in accounts
receivable as a result of increase in sales of which a portion of our increased
sales revenues were from credit sales.

           In the year ended December 31, 2004, cash flow from investing
activities amounted to $35,642. Cash flow from financing activities amounted to
$562,429, mainly due to a decrease in amounts due from shareholders of $569,717,
an increase in amounts owed to stockholders of $184,354, and offset by a
decrease in notes payable.


                                       16
<PAGE>

         The Company is currently funding its operations from, in addition to
sales revenues, loans from shareholders.

         For the year ended December 31, 2004, our Company recorded a net loss
of $219,730. However, among the general and administrative expenses of $415,342,
there were one off expenses of $118,836 for factory relocation expenses and
$78,135 for special audit in Huifeng. Our net loss should narrow down to $22,759
should one time expenses for 2004 did not occur. Also, there was a total of
$94,097 non cash depreciation and amortization expenses for the year ended 2004,
which had no impact on our cash flow. With anticipated increase in sales revenue
in 2005, we believe that the Company should be able to generate positive cash
flow from operations in the operating company level in PRC to support the
on-going operations of the Company. Increase in sales revenue in future together
with our existing cash and cash equivalents balance of $167,511 as of December
31, 2005, we anticipate that it will be sufficient to support the expenditure of
the Company for the next 12 months for the purpose of continuous operations.

Construction in Progress

         As of December 31, 2004, the Company had construction in progress on
the modifications and construction of the Company's factory building for GMP
compliance requirements. Since that date, and prior to the date of this
10-KSB/A, all GMP compliance constructions and modifications have been completed
and all payments related to GMP compliance constructions and modifications have
been settled. The liquidity and financial condition of the Company have not been
impaired subsequent to the settlement of the payments related to completion of
such construction in progress.

Working Capital

         Our working capital deficit amounted to $342,854 at December 31, 2004.
However, our current liabilities in year ended 2004 included a promissory note
of $1,900,000, of which should it be exercised by the bearer, would reduce our
current liabilities from $ 2,314,085 to $414,085 and our working capital should
increase to a surplus of $1,557,146. So, we believe that our existing working
capital level should be able to support the on going operations of the Company
at its current activities level.

         The holders of the Promissory Note have not demanded repayment and on
July 7, 2005 we filed a Form 8-K current report in pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934 to announce that the Promissory
Note was amended and was now due and payable on December 31, 2005. All other
terms and conditions set forth in the Note remain in full force and effect and
are unaffected by this amendment. Also, it is our understanding from the holders
of the Promissory Note that their current and continuing intention is to convert
the Promissory Note into equity of the Company instead of demanding repayment.
As a result, we do not anticipate that the Promissory Note will create liquidity
issues for the Company for the rest of year within 2005.

NEW ACCOUNTING PRONOUNCEMENTS

         In January 2003, (as revised in December 2003) The Financial Accounting
Standards Board ("FASB") issued Interpretation No. 46(R), "Consolidation of
Variable Interest Entities", an interpretation of Accounting Research Bulletin
("ARB") No. 51, "Consolidated Financial Statements". Interpretation No. 46(R)
addresses consolidation by business enterprises of variable interest entities,
which have one or both of the following characteristics: (i) the equity
investment at risk is not sufficient to permit the entity to finance its
activities without additional subordinated support from other parties, which is
provided through other interest that will absorb some or all of the expected
losses of the entity; (ii) the equity investors lack one or more of the
following essential characteristics of a controlling financial interest: the


                                       17
<PAGE>

direct or indirect ability to make decisions about the entities activities
through voting rights or similar rights; or the obligation to absorb the
expected losses of the entity if they occur, which makes it possible for the
entity to finance its activities; the right to receive the expected residual
returns of the entity if they occur, which is the compensation for the risk of
absorbing the expected losses.

         Interpretation No. 46(R), as revised, also requires expanded
disclosures by the primary beneficiary (as defined) of a variable interest
entity and by an enterprise that holds a significant variable interest in a
variable interest entity but is not the primary beneficiary. Interpretation No.
46(R), as revised, applies to small business issuers no later than the end of
the first reporting period that ends after December 15, 2004.

         This effective date includes those entities to which Interpretation 46
had previously been applied. However, prior to the required application of
Interpretation No. 46(R), a public entity that is a small business issuer shall
apply Interpretation 46 or this Interpretation to those entities that are
considered to be special-purpose entities no later than as of the end of the
first reporting period that ends after December 15, 2003.

         Interpretation No. 46(R) may be applied prospectively with a
cumulative-effect adjustment as of the date on which it is first applied or by
restating previously issued financial statements for one or more years with a
cumulative-effect adjustment as of the beginning of the first year restated.

         In May 2003, the FASB issued SFAS No. 150, "Accounting For Certain
Financial Instruments with Characteristics of both Liabilities and Equity". SFAS
No. 150 changes the accounting for certain financial instruments with
characteristics of both liabilities and equity that, under previous
pronouncements, issuers could account for as equity. The new accounting guidance
contained in SFAS No. 150 requires that those instruments be classified as
liabilities in the balance sheet.

         SFAS No. 150 affects the issuer's accounting for three types of
freestanding financial instruments. One type is mandatorily redeemable shares,
which the issuing company is obligated to buy back in exchange for cash or other
assets. A second type includes put options and forward purchase contracts, which
involves instruments that do or may require the issuer to buy back some of its
shares in exchange for cash or other assets. The third type of instruments that
are liabilities under this Statement is obligations that can be settled with
shares, the monetary value of which is fixed, tied solely or predominantly to a
variable such as a market index, or varies inversely with the value of the
issuers' shares. SFAS No. 150 does not apply to features embedded in a financial
instrument that is not a derivative in its entirety.

         Most of the provisions of SFAS 150 are consistent with the existing
definition of liabilities in FASB Concepts Statement No. 6, "Elements of
Financial Statements". The remaining provisions of this Statement are consistent
with the FASB's proposal to revise that definition to encompass certain
obligations that a reporting entity can or must settle by issuing its own
shares. This Statement shall be effective for financial instruments entered into
or modified after May 31, 2003 and otherwise shall be effective at the beginning
of the first interim period beginning after June 15, 2003, except for
mandatorily redeemable financial instruments of a non-public entity, as to which
the effective date is for fiscal periods beginning after December 15, 2004.

         In November 2004, the FASB issued SFAS No. 151 "Inventory Costs". This
statement amends the guidance in ARB No. 43, Chapter 4, "Inventory Pricing," to
clarify the accounting for abnormal amounts of idle facility expense, freight,
handling costs, and wasted material (spoilage). In addition, this Statement
requires that allocation of fixed production overhead to the costs of conversion
be based on the normal capacity of the production facilities. The provisions of
this Statement will be effective for the Company beginning in 2005.

         In December 2004, the FASB issued SFAS No. 153, "Exchanges of
Non-Monetary Assets, an Amendment of Accounting Principles Board ("APB") No.
29". This statement amends APB Opinion No. 29, "Accounting for Nonmonetary


                                       18
<PAGE>

Transactions". Earlier guidance had been based on the principle that exchanges
of nonmonetary assets should be based on the fair value of the assets exchanged
and APB No. 29 included certain exceptions to this principle. However, FASB 153
eliminated the specific exceptions for nonmonetary exchanges with a general
exception rule for all exchanges of nonmonetary assets that do not have
commercial and economic substance. A nonmonetary exchange has commercial
substance only if the future cash flows of the entity is excepted to change
significantly as a result of the exchange. This statement is effective for
nonmonetary exchanges occurring in fiscal periods beginning after June 15, 2005.

         In December 2004, the FASB issued a revised SFAS No. 123, Accounting
for Stock-Based Compensation, which supersedes APB opinion No. 25, Accounting
for Stock Issued to Employees, and its related implementation guidance. This
statement requires a public entity to recognize and measure the cost of employee
services it receives in exchange for an award of equity instruments based on the
grant-date fair value of the award (with limited exceptions). These costs will
be recognized over the period during which an employee is required to provide
service in exchange for the award - the requisite service period (usually the
vesting period). This statement also establishes the standards for the
accounting treatment of these share-based payment transactions in which an
entity exchanges its equity instruments for goods or services. It addresses
transactions in which an entity incurs liabilities in exchange for goods or
services that are based on the fair value of the entity's equity instruments or
that may be settled by the issuance of those equity instruments. This statement
shall be effective the first interim or annual reporting period that begins
after December 15, 2005 for small business public entities and nonpublic
companies.

         The implementations of the above pronouncements are not expected to
have a significant effect on the Company's consolidated financial statement
presentation or disclosure.

INFLATION

         Inflation has not had a material impact on our business.

CURRENCY EXCHANGE FLUCTUATIONS

         All of the Company's revenues and a majority of the expenses in 2004
were denominated primarily in Renminbi ("RMB"), the currency of China. There can
be no assurance that RMB-to-U.S. dollar exchange rates will remain stable. A
devaluation of RMB relative to the U.S. dollar would adversely affect our
business, financial condition and results of operations. We do not engage in
currency hedging.

ITEM 7        FINANCIAL STATEMENTS

            The financial statements, together with the independent auditors'
report thereon, appears beginning on page F-1 of this report.

ITEM 8        CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
              FINANCIAL DISCLOSURES

         There was no change in our certifying accountant for the period of
January 1, 2004 to December 31, 2004.

         On March 14, 2005, the accounting firm of Jimmy C. H. Cheung & Co.,
Certified Public Accountants (a member of Kreston International), 304 Dominion
Centre, 43 Queen's Road East, Hong Kong, was engaged to take over the audit


                                       19
<PAGE>

responsibilities from Epstein Weber & Conover, PLC, certified public accountant;
and Epstein Weber & Conover, PLC was dismissed on that same date.

         During the Company's two most recent fiscal years and any subsequent
interim period prior to the engagement of Jimmy C. H. Cheung & Co., Certified
Public Accountants, the Company has not consulted with Jimmy C. H. Cheung & Co.,
Certified Public Accountants, or any other auditor, regarding any accounting or
audit concerns, to include, but not by way of limitation, those stated in Item
304(a)(2) of Regulation S-B.

         During the Company's two most recent fiscal years and the subsequent
interim period through the date of dismissal, the Company is not aware of any
disagreements with its former accountant, whether resolved or not resolved, on
any matter of accounting principals or practices, financial statement
disclosure, or auditing scope or procedure, which, if not resolved to said
accountants' satisfaction, would have caused it to make reference to the subject
matter of the disagreements(s) in connection with its report.

ITEM 8A     CONTROLS AND PROCEDURES

         The Company maintains disclosure controls and procedures that are
designed to ensure that information required to be disclosed in the Company's
Exchange Act reports is recorded, processed, summarized and reported within the
time periods specified in the SEC's rules and forms, and that such information
is accumulated and communicated to the Company's management, including its Chief
Executive Officer and Chief Financial Officer, as appropriate, to allow timely
decisions regarding required disclosure based closely on the definition of
"disclosure controls and procedures" in Rule 13a-15(c). The Company's disclosure
controls and procedures are designed to provide a reasonable level of assurance
of reaching the Company's desired disclosure control objectives. In designing
and evaluating the disclosure controls and procedures, management recognized
that any controls and procedures, no matter how well designed and operated, can
provide only reasonable assurance of achieving the desired control objectives,
and management necessarily was required to apply its judgment in evaluating the
cost-benefit relationship of possible controls and procedures. The Company's
certifying officer has concluded that the Company's disclosure controls and
procedures are effective in reaching that level of assurance.

         As of the end of the period of this report, the Company carried out an
evaluation, under the supervision and with the participation of the Company's
management, including the Company's Chief Executive Officer and the Company's
Chief Financial Officer, of the effectiveness of the design and operation of the
Company's disclosure controls and procedures. Based on the foregoing, the
Company's Chief Executive Officer and Chief Financial Officer concluded that the
Company's disclosure controls and procedures were effective.

         ITEM 8B  OTHER INFORMATION

         Not applicable.

                                    PART III

ITEM 9        DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS,
              COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

The following table sets forth the names and ages of our current directors and
executive officers, their principal offices and positions and the date each such
person became a director or executive officer of our company. Our executive
officers are elected annually by the Board of Directors. Our directors serve one
year terms until their successors are elected. The executive officers serve
terms of one year or until their death, resignation or removal by the Board of
Directors. There are no family relationships between any of the directors and
executive officers. In addition, there were no arrangements or understanding


                                       20
<PAGE>

between any executive officer and any other person pursuant to which any person
was selected as an executive officer. Currently, directors are not compensated
for serving on the Board of Directors. We have not established compensation or
executive committees. Currently, our entire board of directors serves as our
audit committee. Because of the small size of the Company and the risk attendant
to a small public company, we are currently unable to attract an audit committee
financial expert to our Board of Directors.


RESIGNATION OF DIRECTOR

         On December 20, 2004, subsequent to the Acquisition described in the
Section "History" of "ITEM 1 - DESCRIPTION OF BUSINESS", Art Malone, Jr.
resigned as the Company's Chief Executive Officer, Chief Financial Officer and
any other officer capacity. Mr. Malone resigned as a Director of the Company on
January 28, 2005.

         The resignations were not the result of any known disagreements with
the Company on any matter relating to the Company's operations, policies or
practices.


APPOINTMENT OF NEW DIRECTORS

         The Board of Directors, effective upon Mr. Malone's resignation on
December 20, 2004, appointed Jingan Wang as Chief Executive Officer and
President, Sanding Tao as Chief Financial Officer, and Xinwen Hou as Secretary
and a Director. The Board of Directors appointed the following persons to fill
the vacancies on the Board created by the resignations of the previous
directors:

         Jingan Wang
         Sanding Tao
         Junqi Zhang


BIOGRAPHIES OF OFFICERS AND DIRECTORS

Jingan Wang

      Mr. Jingan Wang, age 44, Chief Executive Officer of the Company, is the
founder and currently serves as President of Huifeng. Mr. Wang has over fifteen
years of experience in accounting and financial management area. Mr. Wang has
served as Accounting Supervisors and Chief Financial Officers for various
companies during his professional career. Before Mr. Wang founded Huifeng in
2000, he was the Chief Financial Officer for Wei Xing Enterprises from 1999 to
2000. Wei Xing Enterprises engages in the pharmaceutical business. Mr. Wang is
also a certified public accountant.

Sanding Tao

         Mr. Sanding Tao, age 36, Chief Financial Officer of the Company and of
Huifeng. Mr. Tao served as VP of Finance and CFO for various technology and
bio-tech firms before he joined Huifeng in 2003. From 1998 - 2000, Mr. Tao
served as Chief Financial Officer for Xian Lan Xi Science & Technology Inc.; and
from 2000 -2003, Mr. Tao served as Chief Financial Officer for Xian Xing Yi
Science & Technology Inc. Xian Lan Xi Science & Technology Inc. engages in the
ambulance modification business. Xian Xing Yi Science & Technology Inc. is a
trading company specializing in medical instruments. Mr. Tao is a graduate of
Chinese Southern Financial College.


                                       21
<PAGE>

Xinwen Hou

         Mr. Xinwen Hou, age 36,Director and Secretary of the Company, currently
also serves as Assistant to the President and as Company Secretary for Huifeng
Biochemistry Joint Stock Company ("Huifeng") in Xian, China. Mr. Hou held
various leadership positions in different public companies in China before he
joined Huifeng in January 2004. From 1997 - 2003, Mr. Hou served as Company
Secretary for De Li Bang Pharmaceutical Inc., which is listed on China's A share
stock exchange. He is also a reputable economist. He graduated from Xian
Transportation University with a major in Business Administration.

         The following table summarizes the information of the directors and
executive officers of our Company:

Name                      Position                        Date Of Appointment
----                      --------                        -------------------
Jingan Wang               Chief Executive Officer         December 20, 2004
Sanding Tao               Chief Financial Officer         December 20, 2004
Xinwen Hou                Director and Secretary          December 20, 2004


INDEMNIFICATION OF DIRECTORS AND OFFICERS

         Our articles of incorporation limit the liability of directors to the
maximum extent permitted by Nevada law. This limitation of liability is subject
to exceptions including intentional misconduct, obtaining an improper personal
benefit and abdication or reckless disregard of director duties. Our articles of
incorporation and bylaws provide that we may indemnify its directors, officer,
employees and other agents to the fullest extent permitted by law. Our bylaws
also permit us to secure insurance on behalf of any officer, director, employee
or other agent for any liability arising out of his or her actions in such
capacity, regardless of whether the bylaws would permit indemnification. We
currently do not have such an insurance policy.

         Insofar as indemnification for liabilities arising under the Securities
Act of 1933 may be permitted for our directors, officers and controlling 1934
persons pursuant to the foregoing provisions, or otherwise, we have been advised
that in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable.

         CODE OF ETHICS

         We have recently adopted a Code of Ethics and Business Conduct
authorizing the establishment of a committee to ensure that our disclosure
controls and procedures remain effective. Our Code also defines the standard of
conduct expected by our officers, directors and employees. The Code is attached
as an exhibit to this report.

ITEM 10.      EXECUTIVE COMPENSATION

      The executives of the Company received no compensation from the Company
for the fiscal year ending December 31, 2004. The Company currently has no
agreements for compensation of its executive, and has no stock option plan or
other equity compensation plan for its employees.

ITEM 11.      SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

         The following table sets forth certain information regarding beneficial
ownership of common stock as of June 15, 2005 by each person known to us to own
beneficially more than 5% of our common stock, each of our directors, each of
our named executive officers; and all executive officers and directors as a
group.


                                       22
<PAGE>

Name                    Position Held              Shares Owned       % Owned
----                    -------------              ------------       -------

Jingan Wang             Chief Executive Officer       37,299,843      39.85%
Sanding Tao             Chief Financial Officer        3,633,102       3.88%
Xinwen Hou              Director and Secretary         3,633,102       3.88%

All directors and executive officers as a group       44,566,047      47.61%

Xian Renfeng Investment Ltd. Co.                       9,284,593       9.92%



            The following table sets forth certain information regarding
beneficial ownership of common stock as of June 15, 2005 by each person known to
us to own beneficially more than 5% of our common stock, each of our directors,
each of our named executive officers; and all executive officers and directors
as a group assuming the conversion of the $1,900,000 Promissory Note into
10,465,725 shares of post 18 for 1 reverse split common stock.



Name                    Position Held                Shares Owned       % Owned
----                    -------------                ------------       -------

Jingan Wang             Chief Executive Officer          7,305,074      46.63%
Sanding Tao             Chief Financial Officer            201,839       1.29%

Xinwen Hou              Director and Secretary           1,248,412       7.97%
Zhang Junqi                                              1,046,573       6.68%
Wang Bijun                                               1,046,573       6.68%
Wang Zhilan                                              1,046,573      6.68.%
Wang Xugang                                              1,046,573       6.68%


All directors and executive officers as a group          8,755,325      55.89%



ITEM 12.      CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

         The Company borrowed funds from Art Malone, Jr., its former sole
officer and director for payment of operating expenses. As a result, during the
three month period ended June 30, 2004 the Company issued 6,232,290 shares of
its common stock to him as repayment for his cash advances and reimbursement for
his services that had accumulated to an amount of approximately $350,000.

         During the three month period ended September 30, 2004, the Company
borrowed an additional $9,600 from Art Malone, Jr. Subsequent to the Acquisition
described in the Section "History" of "ITEM 1 - DESCRIPTION OF BUSINESS", Art
Malone, Jr. waived his claims on the $9,600 loan to the Company.

         The Company had advanced funds totaling $62,493 and $632,210 to
stockholders as of December 31, 2004 and 2003 respectively as short-term,
unsecured loans free of interest payment.

         The details of the short-term, interest free loans granted to
individuals as of December 31, 2003 and 2004 were as follows:


                                       23
<PAGE>

As of December 31, 2004

<TABLE>
<CAPTION>
Name of individual                Amount  Business purpose                         Balance as of    Payment terms
                                                                                   June 13, 2005
--------------------------- ------------- ------------------------------------- ------------------- -----------------------------
<S>                          <C>          <C>                                    <C>                <C>
Qiang Wang                        21,963  Advance: material purchase                            --  Repaid

Bijun Wang                         1,950  Advance: material purchase                            --  Repaid

Xugang Wang                       10,692  Advance: material purchase                            --  Repaid

Gaishi Wang                        2,175  Advance: material purchase                            --  Repaid

Penghui Fan                          783  Advance: material purchase                           783  Repay upon end of business
                                                                                                    trip
Yushan Li                            479  Advance: business trip                               479  Repay upon end of business
                                                                                                    trip
Kangrang Ma                           74  Advance: business trip                                --  Repaid

Guochao Zhi                          298  Advance: business trip                                --  Repaid

Cunpu Ma                           1,207  Advance: business trip                             1,207  Repay upon end of business
                                                                                                    trip
Guozhen Shang                      1,140  Advance: business trip                             1,140  Repay upon end of business
                                                                                                    trip
Bijun Wang                         4,831  Advance: material purchase                         4,831  Repay upon complete of
                                                                                                    purchase
Gengmin Tian                       6,818  Advance: business trip                             6,818  Repay upon end of business
                                                                                                    trip
Xiaogang Zhang                    10,083  Advance: business trip                            10,083  Repay upon end of business
                                                                                                    trip
</TABLE>

As of December 31, 2003

<TABLE>
<CAPTION>
Name of individual                      Amount  Business purpose                          Balance as of  Payment terms
                                                                                          June 13, 2005
---------------------------------- ------------ ------------------------------------ ------------------- -------------------------
<S>                                 <C>         <C>                                   <C>                 <C>
Qiang Wang                              15,991  Advance: material purchase                           --  Repaid
Bijun Wang                              10,976  Advance: material purchase                           --  Repaid
Xugang Wang                                163  Advance: material purchase                           --  Repaid
Gaishi Wang                                117  Advance: material purchase                           --  Repaid
Penghui Fan                              1,232  Advance: material purchase                           --  Repaid
Yushan Li                                  479  Advance: business trip                               --  Repaid
Naihui Wang                             92,156  Advance: material purchase                           --  Repaid
Guochao Zhi                                298  Advance: business trip                               --  Repaid
Xi'an Runfeng Investing                243,249  Advance: business trip                               --  Repaid
Yonghong Ma                             16,030  Advance: business trip                               --  Repaid
Guozhen Shang                            1,141  Advance: business trip                               --  Repaid
Shengwei Miao                          250,378  Advance: business trip                               --  Repaid
</TABLE>

         The majority of these borrowings and short term loans are actually
advances to employees during the normal course of business. It is a normal
practice for Chinese companies to advance funds to employees for company
business purposes. Employees might have to travel throughout different provinces
in China to carry out their duties and from time to time, they need to pay on
behalf of the company (e.g. travel expenses, accommodations, entertainment or


                                       24
<PAGE>

make purchases for the Company). However, there is no widely accepted company
credit card system in much of China and therefore, the Company will advance
funds to employees for such purposes.

         Stockholders had also advanced funds totaling $193,433 and $32,772 to
the Company as of December 31, 2004 and 2003 respectively as short-term,
unsecured loans free of interest payment.

         The breakdown of the shareholders who advanced loans to our Company as
of December 31, 2003 and 2004 is as follows:

As of December 31, 2004

<TABLE>
<CAPTION>
Name of individual                        Amount  Business purpose                 Balance as of  Payment terms
                                                                                   June 13, 2005
------------------------------------ ------------ --------------------------- ------------------- ----------------------------
<S>                                     <C>        <C>                         <C>                 <C>
Kangrang Ma                               15,991  Temporary borrowing                     15,991  July 2005
Heng Li                                   10,976  Temporary borrowing                     10,976  End of June 2005
Xi'an Runfeng Investing                      163  Temporary borrowing                        163  August 2005

As of December 31, 2003

Name of individual                        Amount  Business purpose                 Balance as of  Payment terms
                                                                                   June 13, 2005
------------------------------------ ------------ --------------------------- ------------------- ----------------------------

Kangrang Ma                                9,079  Temporary borrowing                         --  Paid
</TABLE>


         The Company issued a Convertible Promissory Note of $1,900,000 to the
shareholders of Northwest; the Promissory Note is convertible in the Company's
sole discretion into 10,465,725 (post a one for eighteen reverse split and
provided that such reverse split has occured) shares to exchange for 70% of the
outstanding shares of Northwest. The Promissory Note was originally due on June
30, 2005 and has been extended to December 31, 2005. The Promissory Note accrues
interest at the rate of 5% per annum.


ITEM 13.      EXHIBITS

3.1.  Articles of Incorporation (1) 3.2 By Laws (1)
3.3   Certificate of Amendment to Articles of Incorporation (2)
10.1  Stock Purchase Agreement dated as of December 20, 2004 by and among Art
      Malone, Jr., Zhi Lan Wang and Jun Lin (3)
10.2  Agreement and Plan of Reorganization dated as of December 20, 2004 by and
      among Secured Data, Inc., Northwest Bio-Technic Inc., and the shareholders
      of Northwest Bio- Technic Inc.; and Convertible Promissory Note (3)
10.3. Amendment No. 1 to the Convertible Promissory Note Due June 30, 2005 (4)
31.1  Sarbanes Oxley Section 302 Certification of Chief Executive Officer
31.2  Sarbanes Oxley Section 302 Certification of Chief Financial Officer
32.1  Sarbanes Oxley Section 906 Certification of Chief Executive Officer
32.2  Sarbanes Oxley Section 906 Certification of Chief Financial Officer
99.1  Code of Ethics (2)

(1)   Incorporated by reference from the Registration Statement on Form SB-2
      filed on or about July 28, 2000.


                                       25
<PAGE>

(2)   Incorporated by reference from the Annual Report on Form 10-K filed on or
      about June 20, 2005.
(3)   Incorporated by reference from the Current Report on Form 8-K filed on or
      about December 27, 2004.
(4)   Incorporated by reference from the Current Report on Form 8-K filed on or
      about July 7, 2005.


ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

AUDIT FEES

         The aggregate fees billed for each of the last two fiscal years for
professional services rendered by the principal accountant for our audit of
annual financial statements and review of financial statements included in our
Form 10-KSBs and 10-QSBs or services that are normally provided by the
accountant in connection with statutory and regulatory filings or engagements
for those fiscal years was:

2004: $ 20,000    - Jimmy C. H. Cheung & Co.

2003: $ 5,000     - Epstein, Weber & Conover, PLC

AUDIT-RELATED FEES

         For fiscal 2004 and 2003, the Company's auditors did not bill any fees
for assurance and related services that are reasonably related to the
performance of the audit or review of the Company's financial statements and are
not reported under "Audit Fees" above.

TAX FEES

         No fees were billed by the Company's auditors for professional services
for tax compliance, tax advice, and tax planning for fiscal 2004 and 2003,
respectively.

ALL OTHER FEES

         The aggregate fees billed in each of the last two fiscal years for the
products and services provided by the principal accountant, other than the
services reported in paragraph (1) was:

2004: $0          - Jimmy C. H. Cheung & Co.

2003: $3,350      - Epstein, Weber & Conover, PLC

AUDIT COMMITTEE

         The Company's Board of Directors acts as its audit committee, and it
meets prior to filing of any Form 10-QSB or 10-KSB to approve those filings. In
addition, the committee meets to discuss audit plans and anticipated fees for
audit and tax work prior to the commencement of that work. Approximately 100% of
all fees paid to our independent auditors for fiscal 2004 were pre-approved by
the audit committee.


                                       26
<PAGE>

                                   SIGNATURES

         Pursuant to the requirements of Section 13 or 15(d) of the Securities
and Exchange Act, the Registrant has duly caused this Report to be signed on its
behalf by the undersigned thereunto duly authorized.





Date:  July 27, 2005                               By: /s/ Jingan Wang
                                                   Chief Executive Officer


         Pursuant to the requirements of the Securities and Exchange Act of
1934, this Report has been signed below by the following person on behalf of the
Registrant and in the capacities and on the dates indicated.

<TABLE>
<CAPTION>
SIGNATURE           TITLE                                                                   DATE
---------           -----                                                                   ----
<S>                 <C>                                                                     <C>
/s/ Jingan Wang     Chairman and Chief Executive Officer (Principal Executive Officer)      July 27, 2005

/s/ Sanding Tao     Chief Financial Officer (Principal Financial Officer)                   July 27, 2005

/s/ Xinwen Hou      Secretary, Director                                                     July 27, 2005
</TABLE>


                                       27
<PAGE>



                               SECURED DATA, INC.
                                AND SUBSIDIARIES
                              FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)
<PAGE>



                       SECURED DATA, INC. AND SUBSIDIARIES

                                    CONTENTS

                                                                           Pages

Report of Independent Registered Public Accounting Firm                      1

Balance Sheet as of December 31, 2004 (Consolidated and Restated)            2

Statements of Operations and Comprehensive loss for the years
  ended December 31, 2004 (Consolidated and Restated) and 2003               3

Statements of Stockholders' Equity for the years ended December 31, 2004
  (Consolidated and Restated) and 2003                                       4

Statements of Cash Flows for the years ended December 31, 2004
  (Consolidated and Restated) and 2003                                       5

Notes to Consolidated Financial Statements as of December 31, 2004
  (Restated)                                                            6 - 14

<PAGE>

Jimmy C.H. Cheung & Co
Certified Public Accountants
(A member of Kreston International)

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors of:
Secured Data, Inc. and Subsidiaries

We have audited the accompanying balance sheet of Secured Data, Inc. and
subsidiaries as of December 31, 2004 (consolidated) and the related statements
of operations and comprehensive loss, changes in stockholders' equity and cash
flows for the years ended December 31, 2004 (consolidated) and 2003. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.

We conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audits of the financial statements provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Secured Data, Inc. and
subsidiaries, as of December 31, 2004 (consolidated and restated), and the
results of its operations and its cash flows for the years ended December 31,
2004 (consolidated and restated) and 2003, in conformity with accounting
principles generally accepted in the United States of America.

As discussed in Note 2, the accompanying consolidated financial statements for
the year ended December 31, 2004 have been restated.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 14 to
the consolidated financial statements, the Company had a net loss of $219,730,
an accumulated deficit of $2,034,098 and a working capital deficiency of
$342,854 and used cash in operations of $526,363. These factors raise
substantial doubt about its ability to continue as a going concern. Management's
plans concerning this matter are also described in Note 14. The accompanying
consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.




JIMMY C.H. CHEUNG & CO
Certified Public Accountants


Hong Kong

Date: April 11, 2005 except for Note 2, to which the date is June 17, 2005.


         304 Dominion Centre, 43 Queen's Road East, Wanchai, Hong Kong
Tel: (852) 25295500 Fax: (852) 28651067 Email: jchc@krestoninternational.com.hk
                      Website: http://www.jimmycheungco.com


                                       1
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                                  BALANCE SHEET
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)

                                     ASSETS


<TABLE>
<CAPTION>
                                                                                  2004
                                                                         (As Restated)
                                                                          ------------
CURRENT ASSETS
<S>                                                                       <C>
    Cash and cash equivalents                                             $    167,511
    Accounts receivable, net of allowances                                     104,144
    Inventories, net                                                         1,302,025
    Due from stockholders                                                       62,493
    Other assets                                                               335,058
                                                                          ------------
        Total Current Assets                                                 1,971,231

PROPERTY AND EQUIPMENT, NET                                                    879,503

LAND USE RIGHTS, NET                                                           133,974

OTHER ASSETS
    Investment in affiliate                                                     31,190
                                                                          ------------
TOTAL ASSETS                                                              $  3,015,898
                                                                          ------------


                                   LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable                                                      $     56,454
    Other payables and accrued expenses                                        145,191
    Value added tax payables                                                    12,323
    Income tax and other tax payables                                            6,684
    Convertible note payable                                                 1,900,000
    Due to stockholders                                                        193,433
                                                                          ------------
        Total Current Liabilities                                            2,314,085
                                                                          ------------

COMMITMENTS AND CONTINGENCIES                                                       --

MINORITY INTEREST                                                               58,915
                                                                          ------------

STOCKHOLDERS' EQUITY
    Preferred stock, $0.001 par value, 5,000,000 shares authorized,
        none issued and outstanding                                                 --
    Common stock, $0.001 par value, 100,000,000 shares authorized,
        93,604,958 shares issued and outstanding                                93,605
    Additional paid-in capital                                               2,583,391
    Retained earnings (deficit)
      Unappropriated                                                        (2,041,348)
      Appropriated                                                               7,250
                                                                          ------------
        Total Stockholders' Equity                                             642,898
                                                                          ------------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                $  3,015,898
                                                                          ------------
</TABLE>

    The accompanying notes are an integral part of these financial statements


                                       2
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                 STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
   FOR THE YEARS ENDED DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED) AND 2003

<TABLE>
<CAPTION>
                                                                         2004
                                                               (Consolidated)
                                                                (As Restated)            2003
                                                                 ------------    ------------
<S>                                                              <C>             <C>
NET SALES                                                        $  2,478,763    $    715,859

COST OF SALES                                                      (2,235,189)       (683,430)
                                                                 ------------    ------------

GROSS PROFIT                                                          243,574          32,429
                                                                 ------------    ------------

OPERATING EXPENSES
    Selling expenses and distribution expenses                         41,569          49,833
    General and administrative expenses                               415,342          41,729
    Depreciation and amortization                                       9,012           5,543
                                                                 ------------    ------------
           Total Operating Expenses                                   465,923          97,105
                                                                 ------------    ------------

LOSS FROM OPERATIONS                                                 (222,349)        (64,676)

OTHER INCOME (EXPENSES)
    Equity in loss of affiliate                                          (211)             --
    Interest income, net                                                1,260          51,762
    Other income, net                                                     711             272
                                                                 ------------    ------------
           Total Other Income                                           1,760          52,034

                                                                 ------------    ------------
LOSS FROM OPERATIONS BEFORE TAXES AND MINORITY INTEREST              (220,589)        (12,642)

INCOME TAX EXPENSE                                                     (7,503)             --

MINORITY INTEREST                                                       8,362           6,606
                                                                 ------------    ------------

NET LOSS                                                             (219,730)         (6,036)

OTHER COMPREHENSIVE  LOSS
    Foreign currency translation loss                                      --              --
                                                                 ------------    ------------

COMPREHENSIVE LOSS                                               $   (219,730)   $     (6,036)
                                                                 ------------    ------------

Net loss per share-basic and diluted                             $     (0.003)   $         --
                                                                 ------------    ------------

Weighted average number of shares outstanding during the year-
    basic and diluted                                              81,123,434      80,735,590
                                                                 ------------    ------------
</TABLE>


    The accompanying notes are an integral part of these financial statements


                                       3
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                       STATEMENTS OF STOCKHOLDERS' EQUITY
   FOR THE YEARS ENDED DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED) AND 2003

<TABLE>
<CAPTION>
                                                                                                         Additional
                                            Preferred Stock                  Common Stock                  paid-in
                                       Shares           Amount           Shares           Amount           capital
                                   --------------   --------------   --------------   --------------    --------------
<S>                                <C>               <C>             <C>               <C>              <C>
Balance at January 1, 2003                      $               --       80,735,590   $       80,736    $    4,446,260

Net loss for the year                                           --                                --                --
                                   --------------   --------------   --------------   --------------    --------------
Balance at December 31, 2003                   --               --       80,735,590           80,736         4,446,260

Stock issued in recapitalization                                --       12,869,368           12,869          (465,640)

Recapitalization                                                --               --               --        (1,397,229)

Net loss for the year                                           --                                --                --

Transfer to statutory and staff
    welfare reserves                                            --                                --                --
                                   --------------   --------------   --------------   --------------    --------------
Balance at December 31, 2004
(consolidated)                                 --   $           --       93,604,958   $       93,605    $    2,583,391
                                   --------------   --------------   --------------   --------------    --------------
</TABLE>


<TABLE>
<CAPTION>
                                   Unappropriated     Appropriated
                                      retained          retained
                                       deficit          earnings           Total
                                   --------------    --------------    --------------
<S>                                <C>               <C>               <C>
Balance at January 1, 2003         $   (1,808,415)   $           83         2,718,664

Net loss for the year                      (6,036)               --            (6,036)
                                   --------------    --------------    --------------
Balance at December 31, 2003           (1,814,451)               83         2,712,628

Stock issued in recapitalization       (1,397,229)               --        (1,850,000)

Recapitalization                        1,397,229                --                --

Net loss for the year                    (219,730)               --          (219,730)

Transfer to statutory and staff
    welfare reserves                       (7,167)            7,167                --
                                   --------------    --------------    --------------
Balance at December 31, 2004
(consolidated)                     $   (2,041,348)   $        7,250           642,898
                                   --------------    --------------    --------------
</TABLE>

    The accompanying notes are an integral part of these financial statements


                                       4
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                            STATEMENTS OF CASH FLOWS
   FOR THE YEARS ENDED DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED) AND 2003

<TABLE>
<CAPTION>
                                                                                  2004
                                                                          (As Restated)           2003
                                                                          ------------    ------------
<S>                                                                       <C>             <C>
CASH FLOWS FROM OPERATING ACTIVITIES
    Net loss                                                              $   (219,730)   $     (6,036)
    Adjusted to reconcile net loss to cash provided
       by (used in) operating activities:
       Depreciation and amortization - cost of sales                            85,085          72,185
       Depreciation and amortization                                             9,012              --
       Equity in loss of affiliate                                                 211              --
       Minority interest                                                        (8,362)         (6,606)
    Changes in operating assets and liabilities (Increase) decrease in:
       Accounts receivable, net                                                122,023        (178,863)
       Inventories, net                                                       (405,019)        319,450
       Other receivables                                                      (236,920)        (69,131)
       Increase (decrease) in:
       Accounts payable                                                          7,194         (15,876)
       Other payables and accrued expenses                                     101,234         (24,423)
       Value added tax payables                                                 12,323              --
       Income tax and other taxes payable                                        6,586              --
                                                                          ------------    ------------
       Net cash (used in) provided by operating activities                    (526,363)         90,700
                                                                          ------------    ------------

CASH FLOWS FROM INVESTING ACTIVITIES
    Decrease in notes receivable                                               506,774              --
    Decrease (increase) in due from stockholders                               569,717        (133,421)
    Purchase of property and equipment                                        (305,070)        (19,134)
    Investment in affiliate                                                    (31,401)             --
    Acquisition of land use rights                                            (134,661)             --
                                                                          ------------    ------------
       Net cash provided by (used in) investing activities                     605,359        (152,555)
                                                                          ------------    ------------

CASH FLOWS FROM FINANCING ACTIVITIES
    (Decrease) increase in note payable                                       (241,642)         59,806
    Contribution by the stockholders                                            50,000              --
    Increase (decrease) in due to stockholders                                 184,354         (99,317)
                                                                          ------------    ------------
       Net cash provided by (used in) financing activities                      (7,288)        (39,511)
                                                                          ------------    ------------

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS                            71,708        (101,366)

CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR                                  95,803         197,169
                                                                          ------------    ------------

CASH AND CASH EQUIVALENTS AT END OF YEAR                                  $    167,511    $     95,803
                                                                          ------------    ------------

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Cash paid during the year for:
    Income taxes                                                          $     (7,503)   $         --
                                                                          ------------    ------------

    Interest expenses                                                     $         --    $     (2,152)
                                                                          ------------    ------------
</TABLE>



SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

During 2004, the Company issued 80,735,590 shares of common stock for 30% of the
common stock of Northwest.

During 2004, the Company issued a Convertible Promissory Note of $1,900,000 for
70% of the common stock of Northwest.


    The accompanying notes are an integral part of these financial statements


                                       5
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

      (A)   Organization

            Secured Data, Inc. ("Secured Data") is a US listed company which was
            incorporated in Nevada on March 16, 2000 under the name Enternet,
            Inc. On May 23, 2002, the Articles of Incorporation were amended to
            change the name of the Company to Secured Data, Inc.

            Northwest Bio-Technic Inc. ("Northwest") was incorporated in the
            British Virgin Islands ("BVI") on June 25, 2004. Xian Huifeng
            Biochemistry Joint-Stock Company Limited ("Huifeng Biochemistry")
            was incorporated in the People's Republic of China ("PRC") on
            January 20, 2000 as a company with limited liabilities and was
            restructured as a joint stock company on September 29, 2002 under
            the laws of the PRC.

            Huifeng Biochemistry produces plant extracts and bio-chemical
            products used as pharmaceutical raw materials in the PRC. Most of
            its products are distributed within the PRC and some European
            countries.

            On August 23, 2001, Huifeng Biochemistry established a 70% owned
            subsidiary, Xian Huifeng Biochemistry Engineering Company Limited
            ("Huifeng Engineering") in the PRC with a registered capital of
            $265,778. The subsidiary has no operations since its incorporation.

            On June 16, 2004 Huifeng Biochemistry acquired an 86.7% interest in
            Baoji Jinsen Pharmaceutical Company Limited, later renamed to Xian
            Huifeng Pharmaceutical Company Limited ("Huifeng Pharmaceutical"), a
            limited liability company in the PRC. On November 10, 2004 Huifeng
            Pharmaceutical increased its registered capital from $181,159 to
            $603,865. The increased registered capital was fully subscribed by a
            stockholder of the Company, diluting the Company's interest in
            Huifeng Pharmaceutical from 86.7% to 26%.

            During 2004, Huifeng Biochemistry's shareholders exchanged 100% of
            their ownership of Huifeng Biochemistry for 500,000 shares of
            Northwest under a reorganization plan. The transfer has been
            accounted for as a reorganization of entities under common control
            as the companies were beneficially owned by principally identical
            shareholders and share common management.

            On December 20, 2004, pursuant to a Stock Purchase Agreement, a
            Secured Data shareholder sold 7,229,601 shares in Secured Data to
            two Northwest shareholders for $300,000. On the same date, Secured
            Data entered into an Agreement and Plan of Reorganization with the
            shareholders of Northwest to exchange 30% of Northwest's outstanding
            shares for 80,735,590 shares of Secured Data. In addition, the
            Agreement calls for Secured Data to issue a Convertible Promissory
            Note for $1,900,000 that is convertible into 10,465,725 (post a one
            for eighteen reverse split) shares of Secured Data for the remaining
            70% of Northwest. As of April 11, 2005, the Convertible Note has not
            been exercised.

            The merger of Secured Data and Northwest has been recorded as a
            recapitalization by Northwest, with Northwest being treated as the
            continuing entity. The financial statements have been prepared as if
            the reorganization had occurred retroactively. Secured Data,
            Northwest, Huifeng Biochemistry and Huifeng Engineering are
            hereafter referred to as (the "Company"). The transactions were
            treated for accounting purposes as a capital transaction and
            recapitalization by the accounting acquirer ("Northwest") and as a
            reorganization by the accounting acquiree ("Secured Data").

            Accordingly, the financial statements include the following:

            (1)   The balance sheet consists of the net assets of the acquirer
                  at historical cost and the net assets of the acquiree at
                  historical cost.

            (2)   The statement of operations includes the operations of the
                  acquirer for the periods presented and the operations of the
                  acquiree from the date of the merger.


                                       6
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (CONTINUED)

      (B)   Use of estimates

            The preparation of the financial statements in conformity with
            generally accepted accounting principles requires management to make
            estimates and assumptions that affect the reported amount of assets
            and liabilities and disclosure of contingent assets and liabilities
            at the date of the financial statements and the reported amounts of
            revenues and expenses during the reporting period. Actual results
            could differ from those estimates.

      (C)   Principles of consolidation

            The accompanying 2004 consolidated financial statements include the
            accounts of Secured Data and its 100% owned subsidiary Northwest,
            100% owned subsidiary Huifeng Biochemistry, 70% owned subsidiary
            Huifeng Engineering and 86.7% owned subsidiary Huifeng
            Pharmaceutical from the date of its acquisition on June 16, 2004 to
            the date of its dilution in November 10, 2004. The Company accounts
            for its investment in Huifeng Pharmaceutical from November 11, 2004
            to December 31, 2004 under the equity method of accounting. The
            accompanying 2003 financial statements include the accounts of
            Huifeng Biochemistry and its 70% owned subsidiary Huifeng
            Engineering. Minority interest represents the minority shareholders'
            proportionate share of Huifeng Engineering and Huifeng
            Pharmaceutical. All significant inter-company balances and
            transactions have been eliminated in consolidation.

      (D)   Cash and cash equivalents

            For purpose of the statements of cash flows, cash and cash
            equivalents include cash on hand and demand deposits with a bank
            with a maturity of three months or less.

      (E)   Accounts receivable

            The Company extends unsecured credit to its customers in the
            ordinary course of business but mitigates the associated risks by
            performing credit checks and actively pursuing past due accounts. An
            allowance for doubtful accounts is established and recorded based on
            managements' assessment of the credit history with the customer and
            current relationships with them. As of December 31, 2004 the Company
            considers all its accounts receivable to be collectable and no
            provision for doubtful accounts has been made in the financial
            statements.

      (F)   Inventories

            Inventories are stated at the lower of cost or market value, cost
            being determined on a first in, first out method. The Company
            provides for inventory allowances based on excess and obsolete
            inventories determined principally by customer demand.

      (G)   Property and equipment

            Property and equipment are stated at cost, less accumulated
            depreciation. Expenditures for additions, major renewals and
            betterments are capitalized and expenditures for maintenance and
            repairs are charged to expense as incurred.

            Depreciation is provided on a straight-line basis, less estimated
            residual value over the assets' estimated useful lives. The
            estimated useful lives are as follows:

            Plant and machinery                        10 Years
            Motor vehicles                             10 Years
            Furniture, fixtures and equipment           5 Years

            Land use rights are stated at cost, less accumulated amortization.
            The land use rights are amortized over the term of the relevant
            rights of 50 years from the date of acquisition.


                                       7
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (CONTINUED)

      (H)   Long-lived assets

            The Company accounts for long-lived assets under the Statements of
            Financial Accounting Standards Nos. 142 and 144 "Accounting for
            Goodwill and Other Intangible Assets" and "Accounting for Impairment
            or Disposal of Long-Lived Assets" ("SFAS No. 142 and 144"). In
            accordance with SFAS No. 142 and 144, long-lived assets, goodwill
            and certain identifiable intangible assets held and used by the
            Company are reviewed for impairment whenever events or changes in
            circumstances indicate that the carrying amount of an asset may not
            be recoverable. For purposes of evaluating the recoverability of
            long-lived assets, when undiscounted future cash flows will not be
            sufficient to recover an asset's carrying amount, the asset is
            written down to its fair value.

      (I)   Fair value of financial instruments

            Statement of Financial Accounting Standards No. 107, "Disclosure
            About Fair Value of Financial Instruments," requires certain
            disclosures regarding the fair value of financial instruments. Trade
            accounts receivable, accounts payable, and accrued liabilities are
            reflected in the financial statements at fair value because of the
            short-term maturity of the instruments.

      (J)   Revenue recognition

            The Company recognizes revenue upon delivery or shipment of the
            products, at which time title passes to the customer provided that:
            there are no uncertainties regarding customer acceptance; persuasive
            evidence of an arrangement exists; the sales price is fixed or
            determinable; and collectability is deemed probable.

      (K)   Income taxes

            The Company accounts for income taxes under the Statement of
            Financial Accounting Standards No. 109, "Accounting for Income
            Taxes" ("Statement 109"). Under Statement 109, deferred tax assets
            and liabilities are recognized fort the future tax consequences
            attributable to differences between the financial statement carrying
            amounts of existing assets and liabilities and their respective tax
            bases. Deferred tax assets and liabilities are measured using
            enacted tax rates expected to apply to taxable income in the years
            in which those temporary differences are expected to be recovered or
            settled. Under Statement 109, the effect on deferred tax assets and
            liabilities of a change in tax rates is recognized in income in the
            period that included the enactment date.

            PRC income tax is computed according to the relevant laws and
            regulations in the PRC. The Company's subsidiaries being registered
            as a new and high technology enterprise is entitled to an income tax
            reduction. According to the document of reductions approved by the
            local tax bureau, the income tax rate was reduced from 33% to 15% on
            a permanent basis. The income tax expenses for 2004 and 2003 were
            $7,503 and $0 respectively.

      (L)   Foreign currency translation

            The functional currency of the Company is the Chinese Renminbi
            ("RMB"). Transactions denominated in currencies other than RMB are
            translated into United States dollars using year end exchange rates
            as to assets and liabilities and average exchange rates as to
            revenues and expenses. Capital accounts are translated at their
            historical exchange rates when the capital transaction occurred. Net
            gains and losses resulting from foreign exchange translations are
            included in the statements of operations and stockholder's equity as
            other comprehensive income (loss). Cumulative translation adjustment
            amounts were insignificant at and for the years ended December 31,
            2004 and 2003 as the RMB is pegged to the United States dollar.


                                       8
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (CONTINUED)

      (M)   Comprehensive loss

            The foreign currency translation gain or loss resulting from
            translation of the financial statements expressed in RMB to United
            States Dollar is reported as other comprehensive loss in the
            statements of operations and stockholders' equity. Cumulative
            translation adjustment amounts were insignificant at and for the
            years ended December 31, 2004 and 2003.

      (N)   Loss per share

            Basic loss per share is computed by dividing loss available to
            common shareholders by the weighted average number of common shares
            outstanding during the period. Diluted income per share is computed
            similar to basic loss per share except that the denominator is
            increased to include the number of additional common shares that
            would have been outstanding if the potential common shares had been
            issued and if the additional common shares were dilutive.

            The weighted average number of shares used to compute the basic and
            diluted loss per share in these financial statements would
            potentially be further diluted in the future had the convertible
            promissory note of $1,900,000 (note 9) be exercised.


      (O)   Segments

            The Company operates in only one segment, thereafter segment
            disclosure is not presented.

      (P)   Recent Accounting Pronouncements

            Statement of Financial Accounting Standards ("SFAS") No. 151,
            "Inventory Costs - an amendment of ARB No. 43, Chapter 4 SFAS No.
            152, "Accounting for Real Estate Time-Sharing Transactions - an
            amendment of FASB Statements No. 66 and 67," SFAS No. 153,
            "Exchanges of Non-monetary Assets - an amendment of APB Opinion No.
            29," and SFAS No. 123 (revised 2004), "Share-Based Payment," were
            recently issued. SFAS No. 151, 152, 153 and 123 (revised 2004) have
            no current applicability to the Company and have no effect on the
            financial statements.


                                       9
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


2.    RESTATEMENT OF FINANCIAL STATEMENTS

      The Company originally recorded during the year ended December 31, 2004,
      the costs incurred by SCRE prior to the reverse merger as expenses of the
      Company for that year. Under reverse merger accounting such costs should
      be treated as a reduction of additional paid in capital. The Company has
      restated these costs in the Balance Sheet, Statement of Operations,
      Statement of Stockholders' Equity and the Statement of Cash Flows.

      A summary of significant effects of the restatement is as follows:

                                                December 31,
                                                        2004    December 31,
                                              (As Previously            2004
Statement of Operations                            Reported)   (As Restated)
                                                ------------    ------------

Net sales                                       $  2,478,763    $  2,478,763
Cost of sales                                     (2,235,189)     (2,235,189)
Gross profit                                         243,574         243,574
Operating expenses                                   964,637         465,923
Loss from operations                                (721,063)       (222,349)
Other income (expenses)                                1,760           1,760
Income tax expense                                    (7,503)         (7,503)
Minority interest                                      8,362           8,362
Net loss                                            (718,444)       (219,730)
Net loss per share-basic and diluted            $      (0.01)   $     (0.003)
Weighted average number of shares outstanding
    during the year-basic and diluted             81,123,434      81,123,434

                                               December 31,
                                                       2004      December 31,
                                             (As Previously              2004
Balance sheet                                     Reported)     (As Restated)
                                             --------------    --------------

Current assets                               $    1,971,231    $    1,971,231
Property and equipment, net                         879,503           879,503
Land use rights, net                                133,974           133,974
Other assets                                         31,190            31,190
Total assets                                      3,015,898         3,015,898
Current liabilities                               2,314,085         2,314,085
Minority interest                                    58,915            58,915
Stockholders' equity
    Common stock                                     93,605            93,605
    Additional paid-in capital                    3,082,105         2,583,391
    Retained earnings (deficit)
      Unappropriated                             (2,540,062)       (2,041,348)
      Appropriated                                    7,250             7,250
Total liabilities and stockholders' equity   $    3,015,898    $    3,015,898

3.    ACCOUNTS RECEIVABLE

      Accounts receivable at December 31, 2004 consisted of the following:

                                            2004
                                        --------

Accounts receivable                     $104,144
Less: allowance for doubtful accounts         --
                                        --------
Accounts receivable, net                $104,144
                                        --------

      As of December 31, 2004 and 2003, the Company considered all accounts
      receivable collectable and has not recorded a provision for doubtful
      accounts.


                                       10
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


4.    INVENTORIES

      Inventories at December 31, 2004 consisted of the following:

                                              2004
                                        ----------

      Raw materials                     $1,047,781
      Work-in-progress                      11,917
      Finished goods                       242,327
                                        ----------
                                         1,302,025
      Less: provision of obsolescence           --
                                        ----------
                                        $1,302,025
                                        ----------

      For the year ended December 31, 2004 and 2003, the Company did not have
      any obsolete inventories.


5.    OTHER ASSETS

      Other assets at December 31, 2004 consisted of the following:

                                       2004
                                   --------

      Short-term note receivable   $181,159
      Advances to staff              39,227
      Prepayments                    63,018
      Trade deposits paid            32,590
      Other                          19,064
                                   --------
                                   $335,058
                                   --------

6.    PROPERTY AND EQUIPMENT

      The following is a summary of property and equipment at December 31, 2004:

                                                          2004
                                                    ----------

      Plant and machinery                           $  769,476
      Motor vehicles                                    87,262
      Furniture and office equipment                    20,251
      Construction in progress - factory building      286,039
                                                    ----------
                                                     1,163,028
      Less: accumulated depreciation                   283,525
                                                    ----------
      Property and equipment, net                   $  879,503
                                                    ----------

      Depreciation expenses for the years ended December 31, 2004 and 2003 were
      $93,411 and $72,185 respectively.


7.    INVESTMENT IN AFFILIATE

      On June 16, 2004, the Company's subsidiary Xian Huifeng Biochemistry
      Joint-Stock Company Limited ("Huifeng Biochemistry") acquired an 86.7%
      interest in Baoji Jinsen Pharmaceutical Company Limited, later renamed to
      Xian Huifeng Pharmaceutical Company Limited ("Huifeng Pharmaceutical"),
      which owns licenses to manufacture two pharmaceutical products in the PRC.
      The balance of 13.3% is held by a stockholder of the Company. On November
      10, 2004 Huifeng Pharmaceutical increased its registered capital from
      $181,159 to $603,865. The increased registered capital was fully
      subscribed by a stockholder of the Company, diluting the Company's
      interest in Huifeng Pharmaceutical from 86.7% to 26%.


                                       11
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


7.    INVESTMENT IN AFFILIATE (CONTINUED)

      A summary of the unaudited financial statements of the affiliate as of
      December 31, 2004 is as follows:

      Current assets                                         $ 425,641
      Non-current assets                                         1,086
                                                             ---------
      Total assets                                             426,727
                                                             ---------
      Current liabilities                                        4,831
      Stockholders' equity                                     421,896
                                                             ---------
      Total liabilities and stockholders' equity             $ 426,727
                                                             ---------
      Revenue                                                $      --
                                                             ---------
      Net loss from November 11, 2004 to December 31, 2004        (810)
                                                             ---------

      The Company's share of the loss for 2004 :
      Company share at 26% and equity in loss of affiliate   $    (211)
                                                             ---------

8.    OTHER PAYABLES AND ACCRUED EXPENSES

      Other payables and accrued liabilities at December 31, 2004 consist of the
      following:

                                             2004
                                         --------

      Other payables                     $ 24,640
      Accrued expenses                    113,599
      Deposits received from customers      6,952
                                         --------
                                         $145,191
                                         --------

9.    CONVERTIBLE NOTE PAYABLE


     Note payable at December 31, 2004 consists of the following:

                                         2004
                                   ----------

     Convertible Promissory Note   $1,900,000
                                   ----------

     Pursuant to a Convertible Promissory Note, the Company promises to pay to
     Shareholders or their registered assigns, the principal sum of $1,900,000
     on June 30, 2005 or such earlier date as the Convertible Note is required
     or permitted to be repaid as provided hereunder the maturity date, and to
     pay interest to the Holders on the aggregate unconverted and then
     outstanding principal amount of this Convertible Note at the rate of 5% per
     annum, payable on the maturity date as set forth herein. Interest shall be
     calculated on the basis of a 360 day year and shall accrue on the maturity
     date. On the maturity date, the Company may, in its sole discretion, pay
     the principal sum by issuing to the Holder 10,465,725 shares of the
     Company's restricted common stock at $0.1815 per share, provided a required
     1 for 18 reverse stock split of the common stock has been effected. As of
     April 11, 2005, the Convertible Promissory Note has not been exercised.


10.   COMMITMENTS AND CONTINGENCIES

      (A)   Employee benefits

            The full time employees of the Company are entitled to employee
            benefits including medical care, welfare subsidies, unemployment
            insurance and pension benefits through a Chinese government mandated
            multi-employer defined contribution plan. The Company is required to
            accrue for those benefits based on certain percentages of the
            employees' salaries and make contributions to the plans out of the
            amounts accrued for medical and pension benefits. The total
            provision and contributions made for such employee benefits was
            $3,607 and $4,508 for the years ended December 31, 2004 and 2003,
            respectively. The Chinese government is responsible for the medical
            benefits and the pension liability to be paid to these employees.


                                       12
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


10. COMMITMENTS AND CONTINGENCIES (CONTINUED)

(B)      Commitments

         The Company occupies office space from a third party under an operating
         lease which expires on March 2006 at a quarterly rental of $3,080.
         Accordingly, for 2004 and 2003, the Company recognized rental expense
         for this space in the amount of $12,319 and $12,319, respectively.

         As of December 31, 2004, the Company has outstanding commitments with
         respect to non-cancelable operating leases, which are due as follows:


11.   SHAREHOLDERS' EQUITY

      (A)   Stock issuances

            On December 20, 2004 the Company entered into an Agreement and Plan
            of Reorganization with Northwest Bio-Technic Inc ("Northwest") to
            acquire 100% of Northwest equity. The Company issued 80,735,590
            shares in exchange for 30% of Northwest's outstanding shares.

            The Company has authorized up to 5,000,000 shares of preferred stock
            with a par value of $0.001 per share. The preferred stock can be
            issued in various series with varying dividend rates and
            preferences. At December 31, 2004 there are no issued series or
            shares of preferred stock.

      (B)   Appropriated retained earnings

            The Company's wholly owned subsidiary, Huifeng Biochemistry is
            required to make appropriations to reserves funds, comprising the
            statutory surplus reserve, statutory public welfare fund and
            discretionary surplus reserve, based on after-tax net income
            determined in accordance with generally accepted accounting
            principles of the People's Republic of China (the "PRC GAAP").
            Appropriation to the statutory surplus reserve should be at least
            10% of the after tax net income determined in accordance with the
            PRC GAAP until the reserve is equal to 50% of the entities'
            registered capital. Appropriations to the statutory public welfare
            fund are at 5% to 10% of the after tax net income determined in
            accordance with the PRC GAAP. The statutory public welfare fund is
            established for the purpose of providing employee facilities and
            other collective benefits to the employees and is non-distributable
            other than in liquidation. Appropriations to the discretionary
            surplus reserve are made at the discretion of the Board of
            Directors.

            During 2004 and 2003, the Company's wholly owned subsidiary Huifeng
            Biochemistry appropriated $7,167 and $83, respectively to the
            reserves funds based on its net income under PRC GAAP.


12.   RELATED PARTY TRANSACTIONS

      The Company had advanced funds totaling $62,493 and $632,210 to
      stockholders as of December 31, 2004 and 2003 respectively as short-term,
      unsecured loans free of interest payment.

      Stockholders had also advanced funds totaling $193,433 and $9,079 to the
      Company as of December 31, 2004 and 2003 respectively as short-term,
      unsecured loans free of interest payment.

      During 2004, the Company issued 6,232,290 shares of common stock having a
      fair value of $349,008 at $0.056 to a shareholder as repayment of cash
      advances of $373,937 to operate the Company's business. The Company
      recognized operating expenses of $373,937 as of December 31, 2004.

      The Company issued a Convertible Promissory Note of $1,900,000 to the
      shareholders of Northwest, the Note is convertible into 10,465,725 (post a
      one for eighteen reverse split) shares to exchange for 70% of the
      outstanding shares of Northwest.

      See Note 1 (A) for transactions with Northwest and its subsidiaries.


                                       13
<PAGE>

                       SECURED DATA, INC. AND SUBSIDIARIES
                        NOTES TO THE FINANCIAL STATEMENTS
               AS OF DECEMBER 31, 2004 (CONSOLIDATED AND RESTATED)


13.   CONCENTRATIONS AND RISKS

      During 2004 and 2003, 100% of the Company's assets were located in China
      and 90% of the Company's revenues were derived from companies located in
      China.

      The Company relied on two customers for approximately $790,217 and
      $802,324 respectively representing in aggregate 63% of sales for the year
      ended December 31, 2004, and three customers for approximately $78,865,
      $129,710 and 170,870 respectively representing in aggregate 58% of sales
      for the year ended December 31, 2003. At December 31, 2004 and 2003,
      accounts receivable from those customers totaled $32,119 and $149,814
      respectively.

      The Company also relied on four suppliers for approximately $443,718,
      $269,547, $288,832 and $339,895 respectively representing in aggregate 62%
      of purchases for the year ended December 31, 2004, and three suppliers for
      approximately $107,789, $146,781 and $148,827 respectively representing in
      aggregate 72% of purchases for the year ended December 31, 2003. At
      December 31, 2004 and 2003, accounts payable to those two suppliers
      totaled $1,182 and $41,472 respectively.

14.   GOING CONCERN

      As reflected in the accompanying consolidated financial statements, the
      Company has an accumulated deficit of $2,034,098 at December 31, 2004
      which includes a net loss of $219,730 for the year ended December 31,
      2004. The Company's current liabilities exceed its current assets by
      $342,854 and the Company used cash in operation of $526,363. These factors
      raise substantial doubt about its ability to continue as a going concern.
      In view of the matters described above, recoverability of a major portion
      of the recorded asset amounts shown in the accompanying consolidated
      balance sheet is dependent upon continued operations of the company, which
      in turn is dependent upon the Company's ability to raise additional
      capital, obtain financing and succeed in its future operations. The
      financial statements do not include any adjustments relating to the
      recoverability and classification of recorded asset amounts or amounts and
      classification of liabilities that might be necessary should the Company
      be unable to continue as a going concern.

      The Company incurred transaction costs associated with the reverse merger
      of $247,000 and costs associated with the removal of factory of
      approximately $55,000. Total one off expenses of $302,000 made up the 73%
      of total general and administrative expenses without which the Company
      would be profitable.

      The Company is also taking steps to increase its operating capacity and
      service providers to implement its business plan. Management believes that
      actions presently being taken to implement its business plan and generate
      revenues provide the opportunity for the Company to continue as a going
      concern.


15.   SUBSEQUENT EVENT

      On March 23, 2005 the Company's Board of Directors approved, subject to
      the approval of the Company's stockholders, an 18 for 1 reverse split of
      the Company's issued and outstanding common stock and an amendment to its
      Articles of Incorporation changing the name of the Company to "Huifeng
      Bio-pharmaceutical Technology Inc."






                                       14